{"content":"<li class=\"n-box-item date-title\" data-end=\"1484024399\" data-start=\"1483938000\" data-txt=\"Sunday, December 22, 2019\">Monday, January  9, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3234279\" data-ts=\"1484003852\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ILMN\" target=\"_blank\">ILMN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234279-illumina-introduces-new-dna-sequencer-enable-100-genome\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Illumina introduces new DNA sequencer that could enable a $100 genome</a></h4><ul>     <li>Illumina (NASDAQ:<a href='https://seekingalpha.com/symbol/ILMN' title='Illumina, Inc.'>ILMN</a>) <font color='green'>+16.8%</font>&nbsp;AH after saying it is <a href=\"https://seekingalpha.com/pr/16709162-illumina-introduces-novaseq-series-new-architecture-designed-usher-100-genome\" target=\"_blank\">launching a new DNA  sequencer</a> with new architecture it says eventually could push the cost of decoding a human genome to as low as $100.</li>     <li>ILMN says the new DNA sequencers, NovaSeq 5000 and NovaSeq 6000, have lower per sample consumable costs for most sequencing applications than the company's other sequencing systems.</li>     <li>ILMN says the NovaSeq Systems will open up new markets by making routine a wide range of applications, such as ultra-deep sequencing of matched tumor-normal pairs and large-scale variant discovery studies associated with complex diseases.</li><li>#JPM17</li> </ul><div class=\"tiny-share-widget\" data-id=\"3234279\" data-linked=\"Illumina introduces new DNA sequencer that could enable a $100 genome\" data-tweet=\"$ILMN - Illumina introduces new DNA sequencer that could enable a $100 genome https://seekingalpha.com/news/3234279-illumina-introduces-new-dna-sequencer-enable-100-genome?source=tweet\" data-url=\"https://seekingalpha.com/news/3234279-illumina-introduces-new-dna-sequencer-enable-100-genome\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234276\" data-ts=\"1484002436\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ROKA\" target=\"_blank\">ROKA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234276-roka-bioscience-takes-off-up-26-in-late-trade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Roka Bioscience takes off, up 26% in late trade</a></h4><ul>   <li>After heavy volume today (355K shares vs. a typical 78K), Roka Bioscience (<a href='https://seekingalpha.com/symbol/ROKA' title='Roka Bioscience'>ROKA</a> <font color='green'>+7%</font>) is on a run, <font color='green'>up another 26.5%</font> after hours.</li>    <li>The nanocap deals in molecular diagnostics for the detection of pathogens that cause foodborne illnesses, offering the Atlas instrument and Atlas Detection Assays to find foodborne germs. It's moving on no particular news, however.</li>    <li>On Friday, Roka <a href=\"https://seekingalpha.com/filing/3350925\" target=\"_blank\">filed a 13G/A</a> showing that Craig Drill and affiliated funds no longer held an interest in the company.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3234276\" data-linked=\"Roka Bioscience takes off, up 26% in late trade\" data-tweet=\"$ROKA - Roka Bioscience takes off, up 26% in late trade https://seekingalpha.com/news/3234276-roka-bioscience-takes-off-up-26-in-late-trade?source=tweet\" data-url=\"https://seekingalpha.com/news/3234276-roka-bioscience-takes-off-up-26-in-late-trade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:53 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234273\" data-ts=\"1484001335\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234273-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/ILMN' title='Illumina, Inc.'>ILMN</a> <font color='green'>+10.2%</font>. <a href='https://seekingalpha.com/symbol/CUDA' title='Barracuda Networks, Inc'>CUDA</a> <font color='green'>+7.3%</font>. <a href='https://seekingalpha.com/symbol/ARRY' title='Array BioPharma Inc.'>ARRY</a> <font color='green'>+3.2%</font>. <a href='https://seekingalpha.com/symbol/CNDT' title='Conduent Inc'>CNDT</a> <font color='green'>+2.4%</font>. <a href='https://seekingalpha.com/symbol/VOXX' title='VOXX International Corp.'>VOXX</a> <font color='green'>+1.9%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/WMB' title='Williams Companies Inc'>WMB</a> <font color='red'>-7.1%</font>. <a href='https://seekingalpha.com/symbol/FRSH' title='Papa Murphy&#39;s Holdings, Inc.'>FRSH</a> <font color='red'>-7.1%</font>. <a href='https://seekingalpha.com/symbol/WPZ' title='Williams Partners L.P.'>WPZ</a> <font color='red'>-6.5%</font>. <a href='https://seekingalpha.com/symbol/WDFC' title='WD-40 Company'>WDFC</a> <font color='red'>-6.2%</font>. <a href='https://seekingalpha.com/symbol/ATW' title='Atwood Oceanics Inc.'>ATW</a> <font color='red'>-5.6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3234273\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$ILMN $CUDA $ARRY - After Hours Gainers / Losers https://seekingalpha.com/news/3234273-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3234273-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234271\" data-ts=\"1484000729\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WMB\" target=\"_blank\">WMB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234271-williams-to-increase-stake-in-mlp-hikes-dividend-launches-65m-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Williams to increase stake in MLP, hikes dividend, launches 65M-share offering</a></h4><ul><li>Williams Cos. (NYSE:<a href='https://seekingalpha.com/symbol/WMB' title='Williams Companies Inc'>WMB</a>) <font color='red'>-7.1%</font> and Williams Partners (NYSE:<a href='https://seekingalpha.com/symbol/WPZ' title='Williams Partners L.P.'>WPZ</a>) <font color='red'>-6.3%</font>&nbsp;AH after the companies announce a plan to <a href=\"https://seekingalpha.com/pr/16709016-williams-williams-partners-announce-financial-repositioning-long-term-sustainable-growth\" target=\"_blank\">increase WMB's ownership  of WPZ to 72%</a> and for WMB to buy  additional WPZ units in a private placement.</li><li>WMB says it is raising its dividend by 50% to $0.30/share, adding it will target 10%-15% annual growth \"over the next  several years.\"</li><li>WMB also launches a <a href=\"https://seekingalpha.com/pr/16709115-williams-announces-proposed-offering-common-stock\" target=\"_blank\">65M-share public offering</a>, with an underwriters option to purchase up to an additional 9.75M common shares; proceeds will be used to purchase newly issued common units in WPZ at ~$36/unit.</li><li>Effective with the quarterly distribution for the quarter ending March  31, WPZ expects to pay a $0.60 distribution, down 29% from its expected Q4 2016 distribution of $0.85.</li><li>WMB now expects that WPZ will not be required to access the public equity markets \"for the next several years,\" with debt reduction resulting in an improved cash coverage ratio to ~1.2x in 2017  and in excess of 1.1x thereafter.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234271\" data-linked=\"Williams to increase stake in MLP, hikes dividend, launches 65M-share offering\" data-tweet=\"$WMB $WMB $WPZ - Williams to increase stake in MLP, hikes dividend, launches 65M-share offering https://seekingalpha.com/news/3234271-williams-to-increase-stake-in-mlp-hikes-dividend-launches-65m-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3234271-williams-to-increase-stake-in-mlp-hikes-dividend-launches-65m-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>82&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234263\" data-ts=\"1483998747\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZLTQ\" target=\"_blank\">ZLTQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234263-zeltiq-expects-2016-top-line-of-354m-much-425m-this-year-shares-ease-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zeltiq expects 2016 top line of $354M, as much as $425M this year; shares ease 3%</a></h4><ul><li>Zeltiq Aesthetics (NASDAQ:<a href='https://seekingalpha.com/symbol/ZLTQ' title='ZELTIQ Aesthetics, Inc.'>ZLTQ</a>) is off&nbsp;<font color='red'>3%</font>&nbsp;after hours on average volume on the heels of its <a href=\"https://seekingalpha.com/pr/16709035-zeltiq-reports-preliminary-fourth-quarter-full-year-2016-revenue-provides-2017-guidance\" target=\"_blank\">release </a>of preliminary Q4 and full-year results and outlook for 2017.</li><li>Revenues for Q4 and 2016 should come in at $104.5M (+34%) and $354M (+39%), respectively.</li><li>Final results will be released at the end of February.</li><li><strong>2017 guidance</strong>: revenues: $415M - 425M, international revenues: 22% of total, consumables revenues: ~60% of total; gross margin: 70.5 - 71.0% of revenues; non-GAAP EBITDA: 11 - 12% of total.</li><li>Chief Mark Foley will deliver a corporate presentation tomorrow, January 10, at 10:00 am PT at JPM17.</li><li>#JPM17</li></ul><div class=\"tiny-share-widget\" data-id=\"3234263\" data-linked=\"Zeltiq expects 2016 top line of $354M, as much as $425M this year; shares ease 3%\" data-tweet=\"$ZLTQ - Zeltiq expects 2016 top line of $354M, as much as $425M this year; shares ease 3% https://seekingalpha.com/news/3234263-zeltiq-expects-2016-top-line-of-354m-much-425m-this-year-shares-ease-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3234263-zeltiq-expects-2016-top-line-of-354m-much-425m-this-year-shares-ease-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234262\" data-ts=\"1483998708\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CUDA\" target=\"_blank\">CUDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234262-barracuda-networksplus-6_2-after-q3-beats-subscription-growth\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barracuda Networks +6.2% after Q3 beats with subscription growth</a></h4><ul>   <li>Barracuda Networks (<a href='https://seekingalpha.com/symbol/CUDA' title='Barracuda Networks, Inc'>CUDA</a> <font color='green'>+4.4%</font>) is <font color='green'>up 6.2%</font> in late trading after beating on top and bottom lines in its <a href=\"https://seekingalpha.com/news/3234243-barracuda-networks-beats-0_08-beats-revenue\" target=\"_blank\">fiscal Q3 earnings</a>.</li>    <li>Revenue rose nearly 11% and subscription revenue increased 17%, to $68.3M, making up 77% of total revenue. Appliance revenue dipped to $20.5M from the prior year's $21.7M.</li>    <li>Gross billings came to $100.4M, up from a year-ago $89M. Billings from core products beat company expectations, rising 30% to $61.6M.</li>    <li>Active subscribers grew about 15% to more than 309,000; dollar-based renewal rate was 90%.</li>    <li><a href=\"https://seekingalpha.com/pr/16709017-barracuda-reports-third-quarter-fiscal-2017-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3234262\" data-linked=\"Barracuda Networks +6.2% after Q3 beats with subscription growth\" data-tweet=\"$CUDA - Barracuda Networks +6.2% after Q3 beats with subscription growth https://seekingalpha.com/news/3234262-barracuda-networksplus-6_2-after-q3-beats-subscription-growth?source=tweet\" data-url=\"https://seekingalpha.com/news/3234262-barracuda-networksplus-6_2-after-q3-beats-subscription-growth\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:51 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234260\" data-ts=\"1483998400\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HQY\" target=\"_blank\">HQY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234260-big-session-for-healthequity-on-conference-presentation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Big session for HealthEquity on conference presentation</a></h4><ul><li>The company's presentation gets underway at 5:30 ET, but <a href=\"http://files.shareholder.com/downloads/AMDA-2YKW6U/3617091325x0x923240/B63DDB97-CC2F-4977-888D-9B939976A005/JP_Morgan_HC_conf_HQY_Investor_Presentation_Q3_FY17.pdf\" target=\"_blank\">the slides were</a> made public earlier today and they show the number of network partners growing to 671.</li><li>This includes 584 large employers, up 35%, and 87 health plans, up 9%.</li><li><a href='https://seekingalpha.com/symbol/HQY' title='HealthEquity'>HQY</a>&nbsp;<font color='green'>+6.2%</font>&nbsp;on the session.</li><li>#JPM17</li></ul><div class=\"tiny-share-widget\" data-id=\"3234260\" data-linked=\"Big session for HealthEquity on conference presentation\" data-tweet=\"$HQY - Big session for HealthEquity on conference presentation https://seekingalpha.com/news/3234260-big-session-for-healthequity-on-conference-presentation?source=tweet\" data-url=\"https://seekingalpha.com/news/3234260-big-session-for-healthequity-on-conference-presentation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:46 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234259\" data-ts=\"1483998075\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HALO\" target=\"_blank\">HALO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234259-halozyme-down-5_9-after-hours-on-2017-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Halozyme down 5.9% after hours on 2017 guidance</a></h4><ul><li>Halozyme (NASDAQ:<a href='https://seekingalpha.com/symbol/HALO' title='Halozyme Therapeutics, Inc.'>HALO</a>)<font color='green'> rose 6.4%&nbsp;</font>in the regular session amid strong action in the oncology sector after Takeda's purchase of Ariad, but it's&nbsp;<font color='red'>lower by 5.9%</font>&nbsp;after hours <a href=\"https://seekingalpha.com/pr/16709024-halozyme-provides-program-updates-2017-financial-guidance-35th-annual-jp-morgan-healthcare\" target=\"_blank\">following the disclosure of guidance</a> ahead of its JPMorgan Healthcare Conference presentation.</li><li>Full-year 2017 revenue is seen at $115M-$130M, excluding any new ENHANZE global collaboration and licensing agreements that may be signed during the year. The company expects to report $20M in 2016 revenue for reimbursed partner expenses that will not recur in 2017.</li><li>Operating expenses are seen at $240M-$250M this year to support the ongoing Phase 3 study for PEGPH20.</li><li>Year-end cash balance is seen at $100M-$110M.</li><li>The <a href=\"http://www.halozyme.com/investors/default.aspx\" target=\"_blank\">company presents</a> at 6 ET.</li><li>#JPM17</li></ul><div class=\"tiny-share-widget\" data-id=\"3234259\" data-linked=\"Halozyme down 5.9% after hours on 2017 guidance\" data-tweet=\"$HALO - Halozyme down 5.9% after hours on 2017 guidance https://seekingalpha.com/news/3234259-halozyme-down-5_9-after-hours-on-2017-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3234259-halozyme-down-5_9-after-hours-on-2017-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234249\" data-ts=\"1483996808\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FRSH\" target=\"_blank\">FRSH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234249-papa-murphysminus-5_7-after-hours-on-sluggish-numbers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Papa Murphy&#39;s -5.7% after hours on sluggish numbers</a></h4><ul><li>Same-store sales <a href=\"https://seekingalpha.com/pr/16709040-papa-murphy-s-holdings-inc-announces-preliminary-full-year-2016-fourth-quarter-2016-operating\" target=\"_blank\">are seen as down</a> 7.8% during Q4 and 5.2% for the full year.</li><li>The company did open 27 new stores during Q4, bringing full-year openings to 104 vs. 99 opened in 2015.</li><li><a href='https://seekingalpha.com/symbol/FRSH' title='Papa Murphy&#39;s Holdings, Inc.'>FRSH</a>&nbsp;<font color='red'>-5.65%</font>&nbsp;after hours</li></ul><div class=\"tiny-share-widget\" data-id=\"3234249\" data-linked=\"Papa Murphy&#39;s -5.7% after hours on sluggish numbers\" data-tweet=\"$FRSH - Papa Murphy&#39;s -5.7% after hours on sluggish numbers https://seekingalpha.com/news/3234249-papa-murphysminus-5_7-after-hours-on-sluggish-numbers?source=tweet\" data-url=\"https://seekingalpha.com/news/3234249-papa-murphysminus-5_7-after-hours-on-sluggish-numbers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:20 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234247\" data-ts=\"1483996632\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VOXX\" target=\"_blank\">VOXX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234247-voxx-international-eps-in-line-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VOXX International EPS in-line, misses on revenue</a></h4><ul><li>VOXX International (NASDAQ:<a href='https://seekingalpha.com/symbol/VOXX' title='VOXX International Corp.'>VOXX</a>): FQ3 EPS of $0.24 in-line.</li><li>Revenue of $198.9M (+3.3% Y/Y) <font color='red'>misses by $5.1M</font>.</li><li>Shares <font color='green'>+7.5%</font>.</li><li><a href='https://seekingalpha.com/pr/16709079-voxx-international-corporation-reports-fiscal-2017-third-quarter-nine-month-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3234247\" data-linked=\"VOXX International EPS in-line, misses on revenue\" data-tweet=\"$VOXX - VOXX International EPS in-line, misses on revenue https://seekingalpha.com/news/3234247-voxx-international-eps-in-line-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3234247-voxx-international-eps-in-line-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234246\" data-ts=\"1483996555\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATW\" target=\"_blank\">ATW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234246-atwood-oceanics-to-launch-13_5m-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Atwood Oceanics to launch 13.5M-share offering</a></h4><ul>     <li>Atwood Oceanics (NYSE:<a href='https://seekingalpha.com/symbol/ATW' title='Atwood Oceanics Inc.'>ATW</a>) <font color='red'>-5.9%</font>&nbsp;AH after announcing a <a href=\"https://globenewswire.com/news-release/2017/01/09/904555/0/en/Atwood-Oceanics-Inc-Announces-Public-Offering-of-Common-Stock.html\" target=\"_blank\">public offering</a> of 13.5M common shares, with an underwriters option to purchase up to an additional ~2M shares.</li>     <li>ATW says it plans to use the proceeds for general corporate purposes, including the repayment of borrowings under its credit facility, the funding of future  purchases of outstanding 6.5% senior notes due 2020, working capital and capex, and otherwise to enhance liquidity.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3234246\" data-linked=\"Atwood Oceanics to launch 13.5M-share offering\" data-tweet=\"$ATW - Atwood Oceanics to launch 13.5M-share offering https://seekingalpha.com/news/3234246-atwood-oceanics-to-launch-13_5m-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3234246-atwood-oceanics-to-launch-13_5m-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234243\" data-ts=\"1483995833\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CUDA\" target=\"_blank\">CUDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234243-barracuda-networks-beats-0_08-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barracuda Networks beats by $0.08, beats on revenue</a></h4><ul><li>Barracuda Networks (NYSE:<a href='https://seekingalpha.com/symbol/CUDA' title='Barracuda Networks, Inc'>CUDA</a>): FQ3 EPS of $0.22 <font color='green'>beats by $0.08</font>.</li><li>Revenue of $88.8M (+10.9% Y/Y) <font color='green'>beats by $2.21M</font>.</li><li>Shares <font color='green'>+5%</font>.</li><li><a href='https://seekingalpha.com/pr/16709017-barracuda-reports-third-quarter-fiscal-2017-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3234243\" data-linked=\"Barracuda Networks beats by $0.08, beats on revenue\" data-tweet=\"$CUDA - Barracuda Networks beats by $0.08, beats on revenue https://seekingalpha.com/news/3234243-barracuda-networks-beats-0_08-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3234243-barracuda-networks-beats-0_08-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234234\" data-ts=\"1483993988\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EGLT\" target=\"_blank\">EGLT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234234-egalet-gives-up-gains-after-resuming-trade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Egalet gives up gains after resuming trade</a></h4><ul><li><font color='green'>Up more than 15%</font>&nbsp;at the trading halt, and then&nbsp;<font color='green'>rising more than 25%</font>&nbsp;shortly after resuming action, Egalet (<a href='https://seekingalpha.com/symbol/EGLT' title='Egalet Ltd.'>OTC:EGLT</a> <font color='red'>-1.5%</font>) has now given up those gains and turned negative on the session.</li><li>At issue could be the label as the FDA announcement <a href=\"http://www.reuters.com/article/us-egalet-fda-idUSKBN14T209\" target=\"_blank\">didn't say whether</a> the company had been granted the important \"abuse-deterrent\" label.</li><li>Shares appear to be under another volatility halt.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3234228-egalet-confirms-arymo-er-approval-expects-commercial-launch-quarter\" target=\"_blank\">Egalet confirms ARYMO ER approval, expects commercial launch this quarter</a> (Jan. 9)</li></ul><div class=\"tiny-share-widget\" data-id=\"3234234\" data-linked=\"Egalet gives up gains after resuming trade\" data-tweet=\"$EGLT $ZCOR - Egalet gives up gains after resuming trade https://seekingalpha.com/news/3234234-egalet-gives-up-gains-after-resuming-trade?source=tweet\" data-url=\"https://seekingalpha.com/news/3234234-egalet-gives-up-gains-after-resuming-trade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>50&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234229\" data-ts=\"1483993020\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DPLO\" target=\"_blank\">DPLO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234229-diplomat-pharmacys-softer-2016-guidance-pressures-shares-down-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Diplomat Pharmacy&#39;s softer 2016 guidance pressures shares, down 5%</a></h4><ul><li>Diplomat Pharmacy (<a href='https://seekingalpha.com/symbol/DPLO' title='Diplomat Pharmacy'>DPLO</a> <font color='red'>-4.9%</font>) eases on average volume in response to its <a href=\"https://seekingalpha.com/pr/16708026-diplomat-provides-2016-financial-guidance-update\" target=\"_blank\">announcement </a>that it expects 2016 revenues and EBITDA to be at or near the low end of its announced ranges.</li><li>Chairman &amp; CEO Phil Hagerman admits it was a tough year and adds that 2017 doesn't look much better as far as growth is concerned.</li><li>Concurrently, the company announces that it has inked an agreement to acquire Houston, TX-based Affinity Biotech, a specialty pharmacy and infusion services firm focused on hemophilia patients, for $16M in cash and up to $4M in additional contingent consideration. Affinity booked $27M in revenue in 2016. Non-GAAP EBITDA was $3M. The deal should close next month.</li><li>#JPM17</li></ul><div class=\"tiny-share-widget\" data-id=\"3234229\" data-linked=\"Diplomat Pharmacy&#39;s softer 2016 guidance pressures shares, down 5%\" data-tweet=\"$DPLO - Diplomat Pharmacy&#39;s softer 2016 guidance pressures shares, down 5% https://seekingalpha.com/news/3234229-diplomat-pharmacys-softer-2016-guidance-pressures-shares-down-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3234229-diplomat-pharmacys-softer-2016-guidance-pressures-shares-down-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234231\" data-ts=\"1483992998\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UCTT\" target=\"_blank\">UCTT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234231-ultra-clean-holdings-skyrockets-after-lifting-q4-revenue-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ultra Clean Holdings skyrockets after lifting its Q4 revenue guidance</a></h4><ul>     <li>Ultra Clean Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/UCTT' title='Ultra Clean Holdings, Inc.'>UCTT</a>) <a href=\"https://seekingalpha.com/pr/16708391-uct-expects-exceed-fourth-quarter-2016-revenue-guidance\" target=\"_blank\">now expects</a> revenue for Q4 to be ~$173.0M vs. a consensus of $149.0M and previously announced guidance in the range of $146.0 - $151.0M, due to additional customer orders received during the quarter.</li>     <li>The Company expects to release its Q4 and FY16 results on Feb. 22, 2017 after market close.</li><li>Shares&nbsp;<font color='green'>+12%</font></li> </ul><div class=\"tiny-share-widget\" data-id=\"3234231\" data-linked=\"Ultra Clean Holdings skyrockets after lifting its Q4 revenue guidance\" data-tweet=\"$UCTT - Ultra Clean Holdings skyrockets after lifting its Q4 revenue guidance https://seekingalpha.com/news/3234231-ultra-clean-holdings-skyrockets-after-lifting-q4-revenue-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3234231-ultra-clean-holdings-skyrockets-after-lifting-q4-revenue-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234228\" data-ts=\"1483992451\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EGLT\" target=\"_blank\">EGLT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234228-egalet-confirms-arymo-er-approval-expects-commercial-launch-this-quarter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Egalet confirms ARYMO ER approval, expects commercial launch this quarter</a></h4><ul><li>The FDA's approval<a href=\"https://seekingalpha.com/pr/16708965-egalet-receives-fda-approval-arymo-er-morphine-sulfate-c-ii-extended-release-morphine-product\" target=\"_blank\"> triggers the release</a> of $40M in new funding to the company from the second tranche of last August's senior secured debt round.</li><li>ARYMO ER has been approved in three dosage strengths - 15 mg, 30 mg, and 60 mg. Commercial launch is planned for this quarter.</li><li>A <a href=\"http://egalet.investorroom.com/eventsandwebcasts\" target=\"_blank\">conference call </a>is set for this evening at 8:15 ET.</li><li><a href='https://seekingalpha.com/symbol/EGLT' title='Egalet Ltd.'>OTC:EGLT</a> remains under trading halt,&nbsp;<font color='green'>up 15.45%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3234189-egalet-plus-15-percent-shares-halted-fda-approval\" target=\"_blank\">Egalet +15%; shares halted on FDA approval</a> (Jan. 9)</li><li><strong>Update at 3:17:</strong> The trading halt is supposed to come off at 3:30 ET.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234228\" data-linked=\"Egalet confirms ARYMO ER approval, expects commercial launch this quarter\" data-tweet=\"$EGLT $ZCOR - Egalet confirms ARYMO ER approval, expects commercial launch this quarter https://seekingalpha.com/news/3234228-egalet-confirms-arymo-er-approval-expects-commercial-launch-this-quarter?source=tweet\" data-url=\"https://seekingalpha.com/news/3234228-egalet-confirms-arymo-er-approval-expects-commercial-launch-this-quarter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>41&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234226\" data-ts=\"1483992287\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NBY\" target=\"_blank\">NBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234226-novabay-sees-171-jump-in-2016-revenues-shares-ahead-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NovaBay sees 171% jump in 2016 revenues; shares ahead 8%</a></h4><ul><li>Thinly traded nano cap NovaBay Pharmaceuticals (<a href='https://seekingalpha.com/symbol/NBY' title='NovaBay Pharmaceuticals, Inc.'>NBY</a> <font color='green'>+7.6%</font>) perks up on slightly higher volume in response to its <a href=\"https://seekingalpha.com/pr/16708080-novabay-pharmaceuticals-announces-preliminary-sales-fourth-quarter-2016\" target=\"_blank\">release </a>of preliminary Q4 and full-year results.</li><li>It expects revenues of $3.8M (+146%) and $11.8M (+171%), respectively, for the two periods. Final results will be released in March.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234226\" data-linked=\"NovaBay sees 171% jump in 2016 revenues; shares ahead 8%\" data-tweet=\"$NBY - NovaBay sees 171% jump in 2016 revenues; shares ahead 8% https://seekingalpha.com/news/3234226-novabay-sees-171-jump-in-2016-revenues-shares-ahead-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3234226-novabay-sees-171-jump-in-2016-revenues-shares-ahead-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234224\" data-ts=\"1483992020\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234224-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/DDD' title='3D Systems Corp.'>DDD</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/XGTI' title='xG Technology, Inc.'>XGTI</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/ASUR' title='Asure Software, Inc.'>ASUR</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/CYBE' title='CyberOptics Corporation'>CYBE</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/UCTT' title='Ultra Clean Holdings, Inc.'>UCTT</a> <font color='green'>+13%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AYI' title='Acuity Brands, Inc. &#40;Holding Company&#41;'>AYI</a> <font color='red'>-15%</font>. MSDI <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/MEET' title='The Meet Group, Inc.'>MEET</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/OESX' title='Orion Energy Systems, Inc'>OESX</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/MANH' title='Manhattan Associates, Inc.'>MANH</a> <font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3234224\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$DDD $XGTI-OLD $ASUR - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3234224-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3234224-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234221\" data-ts=\"1483991536\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRK\" target=\"_blank\">CRK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234221-comstock-resources-inks-haynesville-shale-joint-venture\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Comstock Resources inks Haynesville shale joint venture</a></h4><ul>     <li>Comstock Resources (<a href='https://seekingalpha.com/symbol/CRK' title='Comstock Resources Inc.'>CRK</a> <font color='red'>-3.3%</font>) says it has entered into a <a href=\"http://phx.corporate-ir.net/phoenix.zhtml?c=101568&amp;p=irol-newsArticle&amp;ID=2234892\" target=\"_blank\">joint development venture</a> with USG Properties to target the Haynesville shale in Louisiana and Texas.</li>     <li>CRK says it will operate wells on acreage recently acquired by USG and manage the drilling program in exchange for a 12.5% working interest in the acreage; CRK can acquire an additional 12.5% interest in each well drilled by reimbursing USG for acreage costs.</li><li>With the addition of the venture, CRK revises its 2017 capital budget to $168.5M and anticipates drilling 24 Haynesville shale wells  in 2017.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3234221\" data-linked=\"Comstock Resources inks Haynesville shale joint venture\" data-tweet=\"$CRK - Comstock Resources inks Haynesville shale joint venture https://seekingalpha.com/news/3234221-comstock-resources-inks-haynesville-shale-joint-venture?source=tweet\" data-url=\"https://seekingalpha.com/news/3234221-comstock-resources-inks-haynesville-shale-joint-venture\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:52 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234220\" data-ts=\"1483991497\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EXEL\" target=\"_blank\">EXEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234220-big-day-for-oncology-players-after-ariad-sale-merck-incyte-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Big day for Oncology players after Ariad sale, Merck/Incyte deal</a></h4><ul><li>NewLink Genetics (<a href=\"https://seekingalpha.com/news/3234167-incyte-7-percent-expanded-cancer-collaboration-merck-ido-competitor-newlink-17-percent\" target=\"_blank\">reported earlier</a>) , Exelixis (<a href='https://seekingalpha.com/symbol/EXEL' title='Exelixis, Inc.'>EXEL</a> <font color='green'>+13.9%</font>), Clovis Oncology (<a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology'>CLVS</a> <font color='green'>+8.5%</font>), Loxo Oncology (<a href='https://seekingalpha.com/symbol/LOXO' title='Loxo Oncology'>LOXO</a> <font color='green'>+7.1%</font>), and Array BioPharma (<a href='https://seekingalpha.com/symbol/ARRY' title='Array BioPharma Inc.'>ARRY</a> <font color='green'>+4.6%</font>) are among those with their tails in the air after <a href=\"https://seekingalpha.com/news/3234076-takeda-takes-ariad-pharma-5_2b\" target=\"_blank\">Takeda takes out Ariad</a> for a&nbsp;<font color='green'>75% premium</font>&nbsp;to Friday's close.</li><li>Also of news in the sector is<a href=\"https://seekingalpha.com/news/3234167-incyte-7-percent-expanded-cancer-collaboration-merck-ido-competitor-newlink-17-percent\" target=\"_blank\"> Incyte's expanded</a> cancer collaboration with Merck.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234220\" data-linked=\"Big day for Oncology players after Ariad sale, Merck/Incyte deal\" data-tweet=\"$EXEL $EXEL $CLVS - Big day for Oncology players after Ariad sale, Merck/Incyte deal https://seekingalpha.com/news/3234220-big-day-for-oncology-players-after-ariad-sale-merck-incyte-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3234220-big-day-for-oncology-players-after-ariad-sale-merck-incyte-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234219\" data-ts=\"1483991323\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HOME\" target=\"_blank\">HOME</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234219-home-group-updates-guidance-in-front-of-icr-talk\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">At Home Group updates guidance in front of ICR talk</a></h4><ul>          <li>At Home Group (<a href='https://seekingalpha.com/symbol/HOME' title='At Home Group'>HOME</a> <font color='green'>+3.6%</font>)&nbsp;announces that it expects sales for FY17 to increase ~22% to a range of $758M to $761M.</li>     <li>Comparable store sales are seen rising 3.0% to 3.2%.</li>     <li>FY17 EPS guidance is&nbsp;narrowed to $0.55 to $0.57. A lower tax rate and share count are positive factors for EPS.</li><li>The company formally presents at ICR tomorrow.</li>     <li><a href=\"https://seekingalpha.com/news/search?query=ICR\" target=\"_blank\">#ICR17</a></li>     <li>Source: <a href=\"https://seekingalpha.com/pr/16708059-home-group-inc-updates-outlook-fiscal-year-2017-ahead-presentation-icr-conference\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3234219\" data-linked=\"At Home Group updates guidance in front of ICR talk\" data-tweet=\"$HOME - At Home Group updates guidance in front of ICR talk https://seekingalpha.com/news/3234219-home-group-updates-guidance-in-front-of-icr-talk?source=tweet\" data-url=\"https://seekingalpha.com/news/3234219-home-group-updates-guidance-in-front-of-icr-talk\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:48 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234218\" data-ts=\"1483991178\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ET\" target=\"_blank\">ET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234218-wsj-blackstones-deal-for-energy-transfer-asset-stake-collapses\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WSJ: Blackstone&#39;s deal for Energy Transfer asset stake collapses</a></h4><ul><li>Talks have fallen through, according to the report, and <a href=\"https://seekingalpha.com/news/3234086-energy-transfer-equity-buys-568m-mlp-units-via-private-placement\" target=\"_blank\">this morning's</a> $568M private placement from Energy Transfer Partners (ETP <font color='red'>-2.1%</font>) was in lieu of the Blackstone (<a href='https://seekingalpha.com/symbol/BX' title='The Blackstone Group L.P.'>BX</a> <font color='red'>-0.6%</font>) deal.</li><li>Energy Transfer Equity (ETE <font color='red'>-5.3%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3234218\" data-linked=\"WSJ: Blackstone&#39;s deal for Energy Transfer asset stake collapses\" data-tweet=\"$ET $ET $BX - WSJ: Blackstone&#39;s deal for Energy Transfer asset stake collapses https://seekingalpha.com/news/3234218-wsj-blackstones-deal-for-energy-transfer-asset-stake-collapses?source=tweet\" data-url=\"https://seekingalpha.com/news/3234218-wsj-blackstones-deal-for-energy-transfer-asset-stake-collapses\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>72&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234217\" data-ts=\"1483990806\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HCA\" target=\"_blank\">HCA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234217-hca-leads-hospitals-higher-after-preliminary-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">HCA leads hospitals higher after preliminary results</a></h4><ul><li>Ahead of its presentation today at the JPMorgan Healthcare Conference, HCA (<a href='https://seekingalpha.com/symbol/HCA' title='HCA Holdings, Inc.'>HCA</a> <font color='green'>+3.2%</font>) announced <a href=\"https://seekingalpha.com/pr/16708396-hca-previews-2016-operating-results\" target=\"_blank\">preliminary full-year </a>adjusted EBITDA of $8.2B, inline with consensus estimates.</li><li>Q4 same-facility admissions up 1.6% Y/Y; same-facility equivalent admissions up 1.5%; same-facility emergency room visits up 1.6%.</li><li>Full results and 2017 guidance are due on Jan. 31.</li><li><a href=\"http://investor.hcahealthcare.com/sites/hcahealthcare.investorhq.businesswire.com/files/event/additional/HCA_healthcare17.pdf\" target=\"_blank\">Presentation slides</a></li><li>Commenting, Mizuho's Sheryl Skolnick says HCA is gaining at the expense of weaker players, \"but at some point,&nbsp;even the best house can&rsquo;t shine as brightly on a dingy block.\" She notes a \"concerning pattern\" of declining ER visit growth, and declines in long-term inpatient volume as \"the real worry\" for hospitals.\" Source: Bloomberg</li><li>Also holding court at JPM, Tenet Health (<a href='https://seekingalpha.com/symbol/THC' title='Tenet Healthcare Corporation'>THC</a> <font color='green'>+4.7%</font>) CEO Trevor Fetter says 1.5% of revenue and 1% of admissions are at risk if the Obamacare exchanges end.</li><li><a href=\"http://investor.tenethealth.com/sites/tenethealth.investorhq.businesswire.com/files/doc_library/file/35th_Annual_J.P._Morgan_Healthcare_Conference_Presentation.pdf\" target=\"_blank\">Presentation slides</a></li><li>#JPM17</li></ul><div class=\"tiny-share-widget\" data-id=\"3234217\" data-linked=\"HCA leads hospitals higher after preliminary results\" data-tweet=\"$HCA $HCA $THC - HCA leads hospitals higher after preliminary results https://seekingalpha.com/news/3234217-hca-leads-hospitals-higher-after-preliminary-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3234217-hca-leads-hospitals-higher-after-preliminary-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234209\" data-ts=\"1483988448\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234209-energy-materials-top-5-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm</a></h4><ul> <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/BCEI' title='Bonanza Creek Energy'>BCEI</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/GORO' title='Gold Resource Corporation'>GORO</a> <font color='green'>+11%</font>. URRE <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/PVG' title='Pretium Resources Inc'>PVG</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/BPT' title='BP Prudhoe Bay Royalty Trust'>BPT</a> <font color='green'>+8%</font>.</li> <li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CDXC' title='ChromaDex Inc.'>CDXC</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/UNT' title='Unit Corporation'>UNT</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/AREX' title='Approach Resources Inc.'>AREX</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/GST' title='Gastar Exploration Inc.'>GST</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/EGY' title='VAALCO Energy, Inc.'>EGY</a> <font color='red'>-7%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3234209\" data-linked=\"Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm\" data-tweet=\"$BCEI $GORO $WWR - Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3234209-energy-materials-top-5-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3234209-energy-materials-top-5-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234202\" data-ts=\"1483986905\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVDA\" target=\"_blank\">NVDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234202-jefferies-increases-to-125-nvidia-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jefferies increases to $125 Nvidia target</a></h4><ul><li><a href=\"http://www.streetinsider.com/Analyst+Comments/NVIDIA+%28NVDA%29+PT+Raised+to+%24125+at+Jefferies%3B+Confident+in+%246Share+Earnings+Power/12405606.html\" target=\"_blank\">Analyst Mark Lipacis</a> moves from <a href=\"https://seekingalpha.com/news/3229996-nvidia-set-110-targets-jefferies-citi\" target=\"_blank\">$110 prior</a>, citing increasing confidence in firm's projection for 3-year EPS power of&nbsp;$6, as self-driving car competition indicates to be heating up subsequent formation of autonomous vehicle collaborations with <a href=\"https://seekingalpha.com/pr/16705626-nvidia-audi-partner-put-worlds-advanced-ai-car-road-2020\" target=\"_blank\">Audi</a> and <a href=\"https://seekingalpha.com/news/3233997-nvidia-mercedes-benz-plan-ai-powered-car-market-within-12-months\" target=\"_blank\">Mercedes-Benz</a>&nbsp;disclosed at CES 2017. Further notes deals previously struck with&nbsp;<a href=\"https://blogs.nvidia.com/blog/2016/10/20/tesla-motors-self-driving/\" target=\"_blank\">Tesla</a>&nbsp;(October 2016)&nbsp;and&nbsp;<a href=\"https://seekingalpha.com/news/3012716-nvidia-unveils-another-car-supercomputer-ces\" target=\"_blank\">Volvo</a>&nbsp;(January 2016).</li><li>Retains Nvidia (<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a> <font color='green'>+3.7%</font>) at Buy.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234202\" data-linked=\"Jefferies increases to $125 Nvidia target\" data-tweet=\"$NVDA - Jefferies increases to $125 Nvidia target https://seekingalpha.com/news/3234202-jefferies-increases-to-125-nvidia-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3234202-jefferies-increases-to-125-nvidia-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234200\" data-ts=\"1483985426\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTLS\" target=\"_blank\">MTLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234200-pacific-crest-securities-reissues-materialise-overweight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pacific Crest Securities reissues Materialise at Overweight</a></h4><ul><li>Projecting Materialise to be \"the fastest-growing company in 3D printing this year,\" <a href=\"http://www.streetinsider.com/Analyst+Comments/Materialise+NV+%28MTLS%29+Should+Be+Fastest-Growing+3D+Printing+Company+in+2017+-+Pacific+Crest/12407242.html\" target=\"_blank\">analyst Weston Twigg</a> highlights recent <a href=\"https://seekingalpha.com/news/3233864-materialise-siemens-partner-additive-manufacturing-technologies\" target=\"_blank\">collaboration with Siemens</a>&nbsp;and discussions held with GE indicating Materialise will remain a robust industry partner. Restates target at $10 (current price $7.30).</li><li>As various 3D issues&nbsp;<a href=\"https://seekingalpha.com/news/3234166-3d-systems-plus-9-percent-trading-active\" target=\"_blank\">trade notably higher</a> today, Materialise (NASDAQ:<a href='https://seekingalpha.com/symbol/MTLS' title='Materialise NV'>MTLS</a>) shares are resisting rally participation and are to this point&nbsp;<font color='red'>lower by 1.75%</font>&nbsp;on the session.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234200\" data-linked=\"Pacific Crest Securities reissues Materialise at Overweight\" data-tweet=\"$MTLS - Pacific Crest Securities reissues Materialise at Overweight https://seekingalpha.com/news/3234200-pacific-crest-securities-reissues-materialise-overweight?source=tweet\" data-url=\"https://seekingalpha.com/news/3234200-pacific-crest-securities-reissues-materialise-overweight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234199\" data-ts=\"1483985245\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMAG\" target=\"_blank\">AMAG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234199-amag-pharmaminus-35-raymond-james-downgrades\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AMAG Pharma -35%; Raymond James downgrades</a></h4><ul><li>Risk/reward is skewed to the downside thanks to another Makena autoinjector snag, says analyst Christopher Raymond, downgrading AMAG Pharmaceuticals (<a href='https://seekingalpha.com/symbol/AMAG' title='AMAG Pharmaceuticals, Inc.'>AMAG</a> <font color='red'>-35.2%</font>) to Underperform.</li><li>The primary source for AMAG's growth and cash flow, Makena loses orphan drug status in February 2018, and the company is discontinuing the comparative pain study for the autoinjector that was supposed to be the main differentiator between Makena and generics.</li><li>Source: Bloomberg</li><li>Previously: <a href=\"https://seekingalpha.com/news/3234103-amag-2016-top-line-may-bit-light-versus-consensus-shares-ease-11-percent-premarket\" target=\"_blank\">AMAG 2016 top line may be a bit light versus consensus; shares ease 11% premarket</a> (Jan. 9)</li><li>The<a href=\"http://ir.amagpharma.com/phoenix.zhtml?c=61596&amp;p=irol-calendar\" target=\"_blank\"> company presents at </a>the JPMorgan Healthcare Conference tomorrow at 2:30 ET.</li><li>#JPM17</li></ul><div class=\"tiny-share-widget\" data-id=\"3234199\" data-linked=\"AMAG Pharma -35%; Raymond James downgrades\" data-tweet=\"$AMAG - AMAG Pharma -35%; Raymond James downgrades https://seekingalpha.com/news/3234199-amag-pharmaminus-35-raymond-james-downgrades?source=tweet\" data-url=\"https://seekingalpha.com/news/3234199-amag-pharmaminus-35-raymond-james-downgrades\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234193\" data-ts=\"1483984850\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234193-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SNFCA' title='Security National Financial Corporation'>SNFCA</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/EHTH' title='eHealth, Inc.'>EHTH</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/OLBK' title='Old Line Bancshares, Inc.'>OLBK</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/EBMT' title='Eagle Bancorp &#40;MT&#41;'>EBMT</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/BOCH' title='Bank of Commerce Holdings &#40;CA&#41;'>BOCH</a> <font color='red'>-7%</font>. WMIH <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/NHLD' title='National Holdings Corp.'>NHLD</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234193\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$SNFCA $EHTH $OLBK - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3234193-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3234193-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234195\" data-ts=\"1483984419\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234195-apple-top-pick-morgan-stanley\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apple a top pick at Morgan Stanley</a></h4><ul><li>Considering focus to be \"too much on near-term supply chain noise\" and not sufficiently on \"iPhone supercycle\" (views China aspect of iPhone debate more so opportunity than risk), prospective cash repatriation and U.S. tax reform catalysts, <a href=\"http://www.streetinsider.com/Analyst+Comments/Morgan+Stanley+Calls+Apple+%28AAPL%29+A+Top+Pick+For+2017%2C+Sees+Growing+List+Of+Catalysts%22%2C+Reiterates+Overweight/12405835.html\" target=\"_blank\">analyst Katy Huberty</a> reissues Apple at Overweight on a $148 target.</li><li>Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>)&nbsp;<font color='green'>+1.05%</font>&nbsp;at $119.14.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234195\" data-linked=\"Apple a top pick at Morgan Stanley\" data-tweet=\"$AAPL - Apple a top pick at Morgan Stanley https://seekingalpha.com/news/3234195-apple-top-pick-morgan-stanley?source=tweet\" data-url=\"https://seekingalpha.com/news/3234195-apple-top-pick-morgan-stanley\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>111&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234192\" data-ts=\"1483984051\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234192-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> ETRM <font color='green'>+85%</font>. <a href='https://seekingalpha.com/symbol/ARIA' title='ARIAD Pharmaceuticals, Inc.'>ARIA</a> <font color='green'>+73%</font>. <a href='https://seekingalpha.com/symbol/WOOF' title='VCA Antech, Inc.'>WOOF</a> <font color='green'>+28%</font>. <a href='https://seekingalpha.com/symbol/BCEI' title='Bonanza Creek Energy'>BCEI</a> <font color='green'>+27%</font>. <a href='https://seekingalpha.com/symbol/NLNK' title='NewLink Genetics Corporation'>NLNK</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/SXE' title='Southcross Energy Partners'>SXE</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/EXAS' title='EXACT Sciences Corporation'>EXAS</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/CYBE' title='CyberOptics Corporation'>CYBE</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/SCAI' title='Surgical Care Affiliates, Inc.'>SCAI</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/EGLT' title='Egalet Ltd.'>OTC:EGLT</a> <font color='green'>+15%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AMAG' title='AMAG Pharmaceuticals, Inc.'>AMAG</a> <font color='red'>-35%</font>. <a href='https://seekingalpha.com/symbol/SSI' title='Stage Stores, Inc.'>SSI</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/CDXC' title='ChromaDex Inc.'>CDXC</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/DXLG' title='Destination XL Group, Inc.'>DXLG</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/AYI' title='Acuity Brands, Inc. &#40;Holding Company&#41;'>AYI</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/AQXP' title='Aquinox Pharmaceuticals, Inc.'>AQXP</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/EGRX' title='Eagle Pharmaceuticals Inc.'>EGRX</a> <font color='red'>-14%</font>. ADHD <font color='red'>-13%</font>. MSDI <font color='red'>-13%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3234192\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$RSLS $ARIA $WOOF - Midday Gainers / Losers https://seekingalpha.com/news/3234192-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3234192-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234191\" data-ts=\"1483983873\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ESPR\" target=\"_blank\">ESPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234191-esperion-launches-cvot-study-of-cholesterol-fighter-bempedoic-acid-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Esperion launches CVOT study of cholesterol fighter bempedoic acid; shares up 2%</a></h4><ul><li>Thinly traded micro cap Esperion Therapeutics (<a href='https://seekingalpha.com/symbol/ESPR' title='Esperion Therapeutics'>ESPR</a> <font color='green'>+1.7%</font>) perks up on more than triple normal volume, albeit on turnover of only 716K shares, in response to the <a href=\"https://seekingalpha.com/pr/16708355-esperion-announces-initiation-global-cardiovascular-outcomes-trial-bempedoic-acid\" target=\"_blank\">initiation </a>of a global cardiovascular outcomes trial &#40;CVOT&#41; assessing the effects of bempedoic acid on the occurrence &nbsp;of major CV events in patients with or at high risk of cardiovascular disease who are considered \"statin intolerant.\"</li><li>The large-scale trial, called CLEAR, will enroll ~12,600 subjects across 600 sites in 30 countries and will run almost five years. The treatment duration will be 3.5 years. If all goes well, the company expects to file marketing applications in the U.S. and Europe by 2022.</li><li><a href=\"http://www.esperion.com/therapies-progress/etc-1002/\" target=\"_blank\">Bempedoic acid</a>&nbsp;is a small molecule that lowers cholesterol without the side effects associated with statins. Once in the liver, it converts into a derivative coenzyme which directly inhibits an enzyme called&nbsp;<a href=\"https://en.wikipedia.org/wiki/ATP_citrate_lyase\" target=\"_blank\">ATP citrate lyase</a>&nbsp;&#40;ACL&#41; which plays a key role in cholesterol and fatty acid synthesis.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234191\" data-linked=\"Esperion launches CVOT study of cholesterol fighter bempedoic acid; shares up 2%\" data-tweet=\"$ESPR - Esperion launches CVOT study of cholesterol fighter bempedoic acid; shares up 2% https://seekingalpha.com/news/3234191-esperion-launches-cvot-study-of-cholesterol-fighter-bempedoic-acid-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3234191-esperion-launches-cvot-study-of-cholesterol-fighter-bempedoic-acid-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:44 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234189\" data-ts=\"1483983439\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EGLT\" target=\"_blank\">EGLT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234189-egaletplus-15-shares-halted-on-fda-approval\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Egalet +15%; shares halted on FDA approval</a></h4><ul><li>The <a href=\"http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=208603\" target=\"_blank\">FDA has approved</a> the NDA for ARYMO.</li><li><a href='https://seekingalpha.com/symbol/EGLT' title='Egalet Ltd.'>OTC:EGLT</a>&nbsp;<font color='green'>+15.55%</font>&nbsp;and currently halted from trade.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3213940-fda-informs-egalet-tomorrows-action-date-arymo-er-met-shares-12-percent-hours\" target=\"_blank\">FDA informs Egalet that tomorrow's action date for ARYMO ER won't be met; shares down 12% after hours</a> (Oct. 13, 2016)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3200677-fda-panel-backs-approval-egalets-abuse-resistant-painkiller\" target=\"_blank\">FDA panel backs approval of Egalet's abuse-resistant painkiller</a> (Aug. 5, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3234189\" data-linked=\"Egalet +15%; shares halted on FDA approval\" data-tweet=\"$EGLT $ZCOR - Egalet +15%; shares halted on FDA approval https://seekingalpha.com/news/3234189-egaletplus-15-shares-halted-on-fda-approval?source=tweet\" data-url=\"https://seekingalpha.com/news/3234189-egaletplus-15-shares-halted-on-fda-approval\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>96&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234187\" data-ts=\"1483983066\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HLTH\" target=\"_blank\">HLTH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234187-nobilis-buys-texas-based-vascular-discease-therapy-provider-for-13_25m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nobilis buys Texas-based vascular discease therapy provider for $13.25M</a></h4><ul><li>Nobilis Health (<a href='https://seekingalpha.com/symbol/HLTH' title='Nobilis Health Corp.'>HLTH</a> <font color='green'>+2%</font>) <a href=\"https://seekingalpha.com/pr/16707985-nobilis-acquire-texas-based-vascular-business\" target=\"_blank\">agrees to acquire</a> Hamilton Vein Center for $13.25M in cash and debt. The provider of clinical and surgical procedures for vascular disease has four locations in the Houston area, one in San Antonio and one in Austin, the latter two represent new markets for Nobilis.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234187\" data-linked=\"Nobilis buys Texas-based vascular discease therapy provider for $13.25M\" data-tweet=\"$HLTH - Nobilis buys Texas-based vascular discease therapy provider for $13.25M https://seekingalpha.com/news/3234187-nobilis-buys-texas-based-vascular-discease-therapy-provider-for-13_25m?source=tweet\" data-url=\"https://seekingalpha.com/news/3234187-nobilis-buys-texas-based-vascular-discease-therapy-provider-for-13_25m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234186\" data-ts=\"1483982914\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BOJA\" target=\"_blank\">BOJA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234186-fast-casual-names-boja-zoes-and-ndls-slump-icr\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fast-casual names BOJA, ZOES and NDLS slump into ICR</a></h4><ul> <li>Investors in Bojangles (<a href='https://seekingalpha.com/symbol/BOJA' title='Bojangles&#39;'>BOJA</a> <font color='red'>-4.5%</font>), Noodles (<a href='https://seekingalpha.com/symbol/NDLS' title='Noodles & Company'>NDLS</a> <font color='red'>-3.4%</font>) and Zoe's Kitchen (<a href='https://seekingalpha.com/symbol/ZOES' title='Zoe&#39;s Kitchen'>ZOES</a> <font color='red'>-8.1%</font>) appear to be taking cover ahead of presentations at the ICR Conference.</li> <li>Some analysts are expecting restaurant companies to lower Q4 and FY17 guidance this week at the event.</li><li><a href=\"https://seekingalpha.com/news/search?query=ICR17\" target=\"_blank\">#ICR17</a></li>   </ul><div class=\"tiny-share-widget\" data-id=\"3234186\" data-linked=\"Fast-casual names BOJA, ZOES and NDLS slump into ICR\" data-tweet=\"$BOJA $BOJA $NDLS - Fast-casual names BOJA, ZOES and NDLS slump into ICR https://seekingalpha.com/news/3234186-fast-casual-names-boja-zoes-and-ndls-slump-icr?source=tweet\" data-url=\"https://seekingalpha.com/news/3234186-fast-casual-names-boja-zoes-and-ndls-slump-icr\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234185\" data-ts=\"1483982487\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHC\" target=\"_blank\">BHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234185-hope-for-valeant-after-takeda-buys-ariad\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hope for Valeant after Takeda buys Ariad?</a></h4><ul><li>Takeda's <a href=\"https://seekingalpha.com/news/3234076-takeda-takes-ariad-pharma-5_2b\" target=\"_blank\">$5.2B purchase of</a> Ariad Pharma this morning might mean a possible deal for Salix or any other Valeant (VRX) assets is off the table, but Takeda CEO Christophe Weber - in an interview at the JPMorgan Healthcare Conference - says there are \"potentially\" more deals to come.</li><li>He acknowledges looking at Salix, but doesn't comment beyond that.</li><li>After opening lower, Valeant is now&nbsp;<font color='green'>up 1.45%</font>&nbsp;on the session.</li><li>#JPM17</li></ul><div class=\"tiny-share-widget\" data-id=\"3234185\" data-linked=\"Hope for Valeant after Takeda buys Ariad?\" data-tweet=\"$BHC - Hope for Valeant after Takeda buys Ariad? https://seekingalpha.com/news/3234185-hope-for-valeant-after-takeda-buys-ariad?source=tweet\" data-url=\"https://seekingalpha.com/news/3234185-hope-for-valeant-after-takeda-buys-ariad\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>111&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234182\" data-ts=\"1483982277\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORCL\" target=\"_blank\">ORCL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234182-oracle-top-2017-large-cap-software-pick-ubs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oracle top 2017 large-cap software pick at UBS</a></h4><ul><li>Analyst Brent Thill considers sentiment and estimates on Oracle at low points and views shares as poised to move nearer to firm's $45 target (current price $39.43) as the company moves all-in on cloud, has yet to realize multiple expansion related to EPS estimates inflection, and EPS and free cash flow stabilize amid cloud revenue trajectory improvement.</li><li>Rates Oracle (<a href='https://seekingalpha.com/symbol/ORCL' title='Oracle Corporation'>ORCL</a> <font color='green'>+2.3%</font>)&nbsp;at Buy.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234182\" data-linked=\"Oracle top 2017 large-cap software pick at UBS\" data-tweet=\"$ORCL - Oracle top 2017 large-cap software pick at UBS https://seekingalpha.com/news/3234182-oracle-top-2017-large-cap-software-pick-ubs?source=tweet\" data-url=\"https://seekingalpha.com/news/3234182-oracle-top-2017-large-cap-software-pick-ubs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234181\" data-ts=\"1483981739\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTIC\" target=\"_blank\">CTIC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234181-cti-biopharmaplus-10-after-presenting-progress-and-plans\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CTI BioPharma +10% after presenting progress and plans</a></h4><ul><li>Recent progress: The FDA this month removed the full clinical hold on studies under the IND application for pacritinib. Also this month, the company received a &euro;7.5M milestone payment for Servier following a milestone associated with patient enrollment in the Phase 3 PIX306 tiral of Pixuvri.</li><li>Among the key objectives for this year:&nbsp;Advance Marketing Authorization Application in E.U. and define regulatory pathway in U.S. for pacritinib;&nbsp;Initiate PAC203 trial (intended for Q2);&nbsp;Secure ex-U.S. partner for pacritinib;&nbsp;Release top-line results of PIX306 (expected by year-end).</li><li>Cash and equivalents on hand at year-end was about $44M (prior to the above-mentioned milestone payment). Cash burn this year is expected to be $65M-$75M. Existing cash and further partnerships should be enough to get through the year, says the company.</li><li><a href=\"https://seekingalpha.com/pr/16707942-cti-biopharma-announces-progress-lead-programs-strategic-objectives-2017\" target=\"_blank\">Full release</a></li><li>#JPM17</li><li><a href='https://seekingalpha.com/symbol/CTIC' title='CTI BioPharma Corp.'>CTIC</a>&nbsp;<font color='green'>+10.55%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3234181\" data-linked=\"CTI BioPharma +10% after presenting progress and plans\" data-tweet=\"$CTIC - CTI BioPharma +10% after presenting progress and plans https://seekingalpha.com/news/3234181-cti-biopharmaplus-10-after-presenting-progress-and-plans?source=tweet\" data-url=\"https://seekingalpha.com/news/3234181-cti-biopharmaplus-10-after-presenting-progress-and-plans\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234180\" data-ts=\"1483981694\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/URBN\" target=\"_blank\">URBN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234180-mall-retailers-bounce-back-from-icr-anxiety\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mall retailers bounce back from ICR anxiety</a></h4><ul> <li>Mall retailers are bouncing back after alarming drops in share price at the end of last week.</li> <li>The mild recovery is taking place in spite of a margin warning from Urban Outfitters (<a href='https://seekingalpha.com/symbol/URBN' title='Urban Outfitters, Inc.'>URBN</a> <font color='red'>-2.4%</font>)&nbsp;in front of the ICR Conference.</li> <li>A decent update from Francesca's (<a href='https://seekingalpha.com/symbol/FRAN' title='Francesca&#39;s Holdings Corp.'>FRAN</a> <font color='green'>+8%</font>)&nbsp;on Q4 sales may be helping to lift sentiment.</li> <li>Gainers include Cato (<a href='https://seekingalpha.com/symbol/CATO' title='The Cato Corporation'>CATO</a> <font color='green'>+3.1%</font>), Buckle (<a href='https://seekingalpha.com/symbol/BKE' title='The Buckle, Inc.'>BKE</a> <font color='green'>+2.7%</font>), Gap (<a href='https://seekingalpha.com/symbol/GPS' title='The Gap, Inc.'>GPS</a> <font color='green'>+2.6%</font>), Express (<a href='https://seekingalpha.com/symbol/EXPR' title='Express, Inc.'>EXPR</a> <font color='green'>+2.2%</font>) and New York &amp; Company (NWY <font color='green'>+2.2%</font>).</li> <li><a href=\"https://seekingalpha.com/news/search?query=ICR17\" target=\"_blank\">&nbsp;#ICR17 updates</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3234180\" data-linked=\"Mall retailers bounce back from ICR anxiety\" data-tweet=\"$URBN $URBN $FRAN - Mall retailers bounce back from ICR anxiety https://seekingalpha.com/news/3234180-mall-retailers-bounce-back-from-icr-anxiety?source=tweet\" data-url=\"https://seekingalpha.com/news/3234180-mall-retailers-bounce-back-from-icr-anxiety\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234179\" data-ts=\"1483981350\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UNH\" target=\"_blank\">UNH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234179-analysts-weigh-in-on-unh-scai-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts weigh in on UNH/SCAI deal</a></h4><ul><li>Analysts like UnitedHealth Group's (<a href='https://seekingalpha.com/symbol/UNH' title='UnitedHealth Group Inc.'>UNH</a> <font color='red'>-0.4%</font>) acquisition of Surgical Health Care Affiliates (<a href='https://seekingalpha.com/symbol/SCAI' title='Surgical Care Affiliates, Inc.'>SCAI</a> <font color='green'>+15.9%</font>) for $57 a share.</li><li>Jefferies' Brian Tanquilut says the bid is fair with competing offers unlikely due to valuation. Great strategic fit with OptumCare.</li><li>Evercore's Michael Newshel adds that OptumCare has \"massive growth potential.\"</li><li>Cowen's Christine Arnold reiterates that OptumHealth is the \"least appreciated\" UNH growth factor. SCAI will supplement Optum's 175 MedExpress clinics.</li><li>Goldman's Matthew Borsch believes SCAI will increase OptumHealth's top line by 8% and operating income 20% before acquisition costs.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234179\" data-linked=\"Analysts weigh in on UNH/SCAI deal\" data-tweet=\"$UNH $UNH $SCAI - Analysts weigh in on UNH/SCAI deal https://seekingalpha.com/news/3234179-analysts-weigh-in-on-unh-scai-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3234179-analysts-weigh-in-on-unh-scai-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234178\" data-ts=\"1483981247\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234178-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <br><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/NLS' title='Nautilus, Inc.'>NLS</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/FFHL' title='Fuwei Films &#40;Holdings&#41; Co., Ltd.'>FFHL</a> <font color='red'>-7%</font>. XNY <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/VUZI' title='Vuzix Corp'>VUZI</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234178\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$NLS $FFHL $DXF - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3234178-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3234178-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234175\" data-ts=\"1483980808\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HLTH\" target=\"_blank\">HLTH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234175-nobillis-health-surgery-partners-on-move-after-surgical-care-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nobillis Health, Surgery Partners on the move after Surgical Care sale</a></h4><ul><li>Surgical Care is&nbsp;<font color='green'>higher by 16%</font>&nbsp;after <a href=\"https://seekingalpha.com/news/3234045-unitedhealth-buys-surgical-care-affiliates-57-share-cash-stock-deal\" target=\"_blank\">agreeing to a sale</a> to UnitedHealth for $2.3B.</li><li>Up alongside are peers Nobillis Health (<a href='https://seekingalpha.com/symbol/HLTH' title='Nobilis Health Corp.'>HLTH</a> <font color='green'>+4.1%</font>) and Surgery Partners (<a href='https://seekingalpha.com/symbol/SGRY' title='Surgery Partners, Inc.'>SGRY</a> <font color='green'>+9.1%</font>).</li><li>Also moving: Tenet Healthcare (<a href='https://seekingalpha.com/symbol/THC' title='Tenet Healthcare Corporation'>THC</a> <font color='green'>+4.6%</font>), Universal Health (<a href='https://seekingalpha.com/symbol/UHS' title='Universal Health Services Inc.'>UHS</a> <font color='green'>+2%</font>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3234175\" data-linked=\"Nobillis Health, Surgery Partners on the move after Surgical Care sale\" data-tweet=\"$HLTH $HLTH $SGRY - Nobillis Health, Surgery Partners on the move after Surgical Care sale https://seekingalpha.com/news/3234175-nobillis-health-surgery-partners-on-move-after-surgical-care-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3234175-nobillis-health-surgery-partners-on-move-after-surgical-care-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:53 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234174\" data-ts=\"1483980702\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BABY\" target=\"_blank\">BABY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234174-natus-expects-bullish-2017-shares-ahead-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Natus expects bullish 2017; shares ahead 5%</a></h4><ul><li>On a preliminary basis, Natus Medical (<a href='https://seekingalpha.com/symbol/BABY' title='Natus Medical Incorporated'>BABY</a> <font color='green'>+4.8%</font>) <a href=\"https://seekingalpha.com/pr/16708142-natus-medical-announces-2017-annual-first-quarter-financial-guidance\" target=\"_blank\">expects </a>Q4 revenues of $107.5 - 108.0M and $381.2M - 383.2M for 2016, both in line with consensus.</li><li><strong>2017 guidance</strong>: revenues: $505.0M - 510.0M (consensus: $428.0M); non-GAAP EPS: $1.80 - 1.85 (consensus: $1.85).</li><li><strong>Q1 guidance</strong>: revenues: $122.0M - 124.0M; non-GAAP EPS: $0.32 - 0.34.</li><li>Final 2016 results will be released before the open on February 1.</li><li>$JPM17</li></ul><div class=\"tiny-share-widget\" data-id=\"3234174\" data-linked=\"Natus expects bullish 2017; shares ahead 5%\" data-tweet=\"$BABY $NTUS - Natus expects bullish 2017; shares ahead 5% https://seekingalpha.com/news/3234174-natus-expects-bullish-2017-shares-ahead-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3234174-natus-expects-bullish-2017-shares-ahead-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:51 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234172\" data-ts=\"1483980266\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GPN\" target=\"_blank\">GPN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234172-global-payments-spikes-to-all-time-high\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Global Payments spikes to all-time high</a></h4><ul> <li>Global Payments (<a href='https://seekingalpha.com/symbol/GPN' title='Global Payments Inc.'>GPN</a> <font color='green'>+6.9%</font>) rallies after posting a FQ2 earnings beat and setting pleasing guidance.</li> <li>Global sees 2017 revenue of $3.35B-$3.45B and EPS of $3.70-$3.90.</li> <li>The company also lifted its buyback authorization to $300M.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3234046-global-payments-beats-0_04-beats-revenue\" target=\"_blank\">Global Payments beats by $0.04, beats on revenue</a> (Jan. 9)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3234172\" data-linked=\"Global Payments spikes to all-time high\" data-tweet=\"$GPN - Global Payments spikes to all-time high https://seekingalpha.com/news/3234172-global-payments-spikes-to-all-time-high?source=tweet\" data-url=\"https://seekingalpha.com/news/3234172-global-payments-spikes-to-all-time-high\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234171\" data-ts=\"1483980207\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ENDP\" target=\"_blank\">ENDP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234171-endo-internationalplus-2_1-after-jpm-conference-slides\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Endo International +2.1% after JPM conference slides</a></h4><ul><li>The company reaffirms full-year guidance: revenue of $3.87B-$4.03B, adjusted gross margin about 60%, and adjusted EPS of $4.50-$4.80.</li><li>Also part of the talking points: Statistically significant Phase IIb results for Xiaflex in cellulite, key FTF launches of generic Seroquel and generic Zeita, and progress on the strategic review.</li><li><a href=\"https://seekingalpha.com/filing/3351515\" target=\"_blank\">Presentation slides</a></li><li><a href=\"http://www.endo.com/investors/overview\" target=\"_blank\">The presentation begins </a>at 1:30 ET.</li><li><a href='https://seekingalpha.com/symbol/ENDP' title='Endo International plc'>ENDP</a>&nbsp;<font color='green'>+2.1%</font></li><li>#JPM17</li></ul><div class=\"tiny-share-widget\" data-id=\"3234171\" data-linked=\"Endo International +2.1% after JPM conference slides\" data-tweet=\"$ENDP - Endo International +2.1% after JPM conference slides https://seekingalpha.com/news/3234171-endo-internationalplus-2_1-after-jpm-conference-slides?source=tweet\" data-url=\"https://seekingalpha.com/news/3234171-endo-internationalplus-2_1-after-jpm-conference-slides\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234167\" data-ts=\"1483979884\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INCY\" target=\"_blank\">INCY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234167-incyte-up-7-on-expanded-cancer-collaboration-merck-ido-competitor-newlink-up-17\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Incyte up 7% on expanded cancer collaboration with Merck; IDO competitor NewLink up 17%</a></h4><ul><li>Incyte (<a href='https://seekingalpha.com/symbol/INCY' title='Incyte Corporation'>INCY</a> <font color='green'>+6.7%</font>) and Merck (<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a> <font color='green'>+0.4%</font>) expand their <a href=\"https://seekingalpha.com/pr/16708285-incyte-merck-advance-clinical-development-program-investigating-combination-epacadostat\" target=\"_blank\">collaboration</a> investigating the combination of epacadostat and Keytruda (pembrolizumab) in solid tumors and blood cancers. The companies now plan to initiate pivotal studies in four additional tumor types: non-small cell lung cancer, renal cell carcinoma, bladder cancer and squamous cell carcinoma.</li><li>Epacadostat is a small molecule inhibitor of&nbsp;<a href=\"https://en.wikipedia.org/wiki/Indoleamine_2,3-dioxygenase\" target=\"_blank\">IDO1</a>, an immunosuppressive enzyme that has been shown to induce regulatory T cell generation and activation thereby allowing cancer cells to avoid detection by the immune system. Pembrolizumab&nbsp;helps the immune system fight tumor cells by blocking the interaction between&nbsp;<a href=\"https://en.wikipedia.org/wiki/Programmed_cell_death_1\" target=\"_blank\">PD-1</a>, a cell surface receptor expressed on T cells and pro-B cells, and its ligands PD-L1 and PD-L2. PD-1 is an immune checkpoint which down regulates the immune system. Blocking its action activates the immune system to attack cancer cells.</li><li>The good news has apparently spread to NewLink Genetics (<a href='https://seekingalpha.com/symbol/NLNK' title='NewLink Genetics Corporation'>NLNK</a> <font color='green'>+17.1%</font>) who inked a <a href=\"http://www.newlinkgenetics.com/collaboration/\" target=\"_blank\">development deal</a> in October 2014 with Roche's (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding Ltd ADR'>OTCQX:RHHBY</a>) Genentech for IDO candidate GDC-0919.</li><li>#JPM17</li></ul><div class=\"tiny-share-widget\" data-id=\"3234167\" data-linked=\"Incyte up 7% on expanded cancer collaboration with Merck; IDO competitor NewLink up 17%\" data-tweet=\"$INCY $INCY $MRK - Incyte up 7% on expanded cancer collaboration with Merck; IDO competitor NewLink up 17% https://seekingalpha.com/news/3234167-incyte-up-7-on-expanded-cancer-collaboration-merck-ido-competitor-newlink-up-17?source=tweet\" data-url=\"https://seekingalpha.com/news/3234167-incyte-up-7-on-expanded-cancer-collaboration-merck-ido-competitor-newlink-up-17\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:38 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234170\" data-ts=\"1483979768\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PETX\" target=\"_blank\">PETX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234170-mars-deal-throws-spotlight-on-pet-care-sector\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mars deal throws a spotlight on the pet care sector</a></h4><ul> <li>Shares of Artana Therapeutics (<a href='https://seekingalpha.com/symbol/PETX' title='Aratana Therapeutics'>PETX</a> <font color='green'>+8.5%</font>) catch a bid after pet services peer VCA Antech is bought out by Mars.</li> <li>Artana trades at its highest level since last October.</li> <li>A deep dive into recent trends in the pet care sector was <a href=\"https://seekingalpha.com/article/2898446-profit-from-trends-in-the-pet-care-industry\" target=\"_blank\">posted</a> on Seeking Alpha earlier today by Willow Street Investments.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3234074-mars-acquires-vca-antech-inc\" target=\"_blank\">Mars acquires VCA Antech Inc.</a> (Jan. 9)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3234147-mars-vca-deal-seen-sailing-past-regulatory-review\" target=\"_blank\">Mars-VCA deal seen sailing past regulatory review</a> (Jan. 9)</li> <li>Related stocks: <a href='https://seekingalpha.com/symbol/ABC' title='AmerisourceBergen Corporation'>ABC</a>, <a href='https://seekingalpha.com/symbol/HSIC' title='Henry Schein, Inc.'>HSIC</a>, <a href='https://seekingalpha.com/symbol/MWIV' title='MWI Veterinary Supply, Inc.'>MWIV</a>, <a href='https://seekingalpha.com/symbol/PDCO' title='Patterson Companies Inc.'>PDCO</a>, <a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a>, <a href='https://seekingalpha.com/symbol/SJM' title='J. M. Smucker Company'>SJM</a>, <a href='https://seekingalpha.com/symbol/ZTS' title='Zoetis'>ZTS</a>, <a href='https://seekingalpha.com/symbol/BUFF' title='Blue Buffalo'>BUFF</a>, <a href='https://seekingalpha.com/symbol/FRT' title='Federal Realty Investment Trust'>FRT</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3234170\" data-linked=\"Mars deal throws a spotlight on the pet care sector\" data-tweet=\"$PETX $PETX $ABC - Mars deal throws a spotlight on the pet care sector https://seekingalpha.com/news/3234170-mars-deal-throws-spotlight-on-pet-care-sector?source=tweet\" data-url=\"https://seekingalpha.com/news/3234170-mars-deal-throws-spotlight-on-pet-care-sector\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234169\" data-ts=\"1483979668\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KERX\" target=\"_blank\">KERX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234169-keryx-biopharmaplus-5_4-on-strong-preliminary-numbers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Keryx Biopharma +5.4% on strong preliminary numbers</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/16707910-keryx-biopharmaceuticals-announces-recent-business-progress-reviews-corporate-strategy-35th\" target=\"_blank\">Q4 prescription demand</a> was about 8.7K prescriptions, which included 4.5K for December, the first full month of sales post resupply of Auryxia. The FDA has also approved Patheon's manufacturing facility in France which will supply Auryxia to the U.S.</li><li>Keryx (<a href='https://seekingalpha.com/symbol/KERX' title='Keryx Biopharmaceuticals, Inc.'>KERX</a> <font color='green'>+5.4%</font>) expects Q4 revenues of about $9.5M vs. $5.8M a year earlier. Full-year revenues should foot to $31.9M vs. $13.7M in 2015.</li><li>Cash and cash equivalents totaled about $112.1M at year-end.</li><li>The company's <a href=\"http://investors.keryx.com/phoenix.zhtml?c=122201&amp;p=irol-EventDetails&amp;EventId=5245396\" target=\"_blank\">JPMorgan conference presentation</a> is at 5:30 ET.</li><li>#JPM17</li></ul><div class=\"tiny-share-widget\" data-id=\"3234169\" data-linked=\"Keryx Biopharma +5.4% on strong preliminary numbers\" data-tweet=\"$KERX - Keryx Biopharma +5.4% on strong preliminary numbers https://seekingalpha.com/news/3234169-keryx-biopharmaplus-5_4-on-strong-preliminary-numbers?source=tweet\" data-url=\"https://seekingalpha.com/news/3234169-keryx-biopharmaplus-5_4-on-strong-preliminary-numbers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234168\" data-ts=\"1483979605\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BCEI\" target=\"_blank\">BCEI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234168-bonanza-creek-energyplus-25-fir-tree-buys-3_6m-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bonanza Creek Energy +25% as Fir Tree buys 3.6M shares</a></h4><ul><li>Bonanza Creek Energy (<a href='https://seekingalpha.com/symbol/BCEI' title='Bonanza Creek Energy'>BCEI</a> <font color='green'>+25.3%</font>) explodes higher after major shareholder Fir Tree reports the <a href=\"http://www.streetinsider.com/SEC+Filings/Form+4+Bonanza+Creek+Energy%2C+For%3A+Jan+04+Filed+by%3A+FIR+TREE+INC./12403705.html\" target=\"_blank\">purchase of more than 3.6M shares</a>, in a transaction occurring last Thursday.</li><li>The shares were bought at  an average $1.34/share, for a total of ~$4.85M.</li><li>Shares have more than doubled since BCEI announced <a href=\"https://seekingalpha.com/news/3233421-bonanza-creek-sees-emergence-chapter-11-end-q1\" target=\"_blank\">last Wednesday</a> that it expects to emerge from Chapter 11 bankruptcy before the end of Q1.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234168\" data-linked=\"Bonanza Creek Energy +25% as Fir Tree buys 3.6M shares\" data-tweet=\"$BCEI - Bonanza Creek Energy +25% as Fir Tree buys 3.6M shares https://seekingalpha.com/news/3234168-bonanza-creek-energyplus-25-fir-tree-buys-3_6m-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3234168-bonanza-creek-energyplus-25-fir-tree-buys-3_6m-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>37&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234166\" data-ts=\"1483979448\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SSYS\" target=\"_blank\">SSYS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234166-3d-systemsplus-9-trading-active\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">3D Systems +9%, trading active</a></h4><ul><li>With no material news, M&amp;A speculation is vaguely circulating. 3D Systems share volume on the session is strong, presently at a 3.25M level over the <a href=\"https://www.google.com/finance?q=NYSE:DDD\" target=\"_blank\">daily average of 2.05M</a>.</li><li><strong>3D peers</strong> &ndash; Stratasys (<a href='https://seekingalpha.com/symbol/SSYS' title='Stratasys, Inc.'>SSYS</a> <font color='green'>+3.5%</font>), ExOne (<a href='https://seekingalpha.com/symbol/XONE' title='ExOne'>XONE</a> <font color='green'>+4.3%</font>), Voxeljet (<a href='https://seekingalpha.com/symbol/VJET' title='voxeljet AG'>VJET</a> <font color='green'>+2%</font>), Materialise (<a href='https://seekingalpha.com/symbol/MTLS' title='Materialise NV'>MTLS</a> <font color='red'>-0.8%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3234166\" data-linked=\"3D Systems +9%, trading active\" data-tweet=\"$SSYS $SSYS $XONE - 3D Systems +9%, trading active https://seekingalpha.com/news/3234166-3d-systemsplus-9-trading-active?source=tweet\" data-url=\"https://seekingalpha.com/news/3234166-3d-systemsplus-9-trading-active\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234134\" data-ts=\"1483977832\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234134-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> ETRM <font color='green'>+96%</font>. <a href='https://seekingalpha.com/symbol/ARIA' title='ARIAD Pharmaceuticals, Inc.'>ARIA</a> <font color='green'>+73%</font>. <a href='https://seekingalpha.com/symbol/PTX' title='Pernix Therapeutics Holdings, Inc.'>PTX</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/EXAS' title='EXACT Sciences Corporation'>EXAS</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/NLNK' title='NewLink Genetics Corporation'>NLNK</a> <font color='green'>+19%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AMAG' title='AMAG Pharmaceuticals, Inc.'>AMAG</a> <font color='red'>-32%</font>. ADHD <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/AGIO' title='Agios Pharmaceuticals, Inc.'>AGIO</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/AQXP' title='Aquinox Pharmaceuticals, Inc.'>AQXP</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/ATRC' title='AtriCure, Inc.'>ATRC</a> <font color='red'>-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3234134\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$RSLS $ARIA $PTX-OLD - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3234134-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3234134-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234152\" data-ts=\"1483977607\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTE\" target=\"_blank\">PTE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234152-majesco-entertainment-gets-delisting-warning-over-independent-directors\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Majesco Entertainment gets delisting warning over independent directors</a></h4><ul>   <li>Majesco Entertainment (<a href=\"https://seekingalpha.com/symbol/COOL\" target=\"_blank\">COOL</a> <font color='green'>+2%</font>) says it's gotten a warning from Nasdaq over its board constitution.</li>    <li>In a <a href=\"https://seekingalpha.com/filing/3351159\" target=\"_blank\">filing</a>, the company says it's gotten a noncompliance letter regarding a listing rule requiring that a majority of directors be considered independent.</li>    <li>The company -- in the process of becoming Polarity through an acquisition of PolarityTE -- has until Feb. 21 to submit a compliance plan, and it says that it plans to appoint additional independent directors in conjunction with the acquisition.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3234152\" data-linked=\"Majesco Entertainment gets delisting warning over independent directors\" data-tweet=\"$PTE - Majesco Entertainment gets delisting warning over independent directors https://seekingalpha.com/news/3234152-majesco-entertainment-gets-delisting-warning-over-independent-directors?source=tweet\" data-url=\"https://seekingalpha.com/news/3234152-majesco-entertainment-gets-delisting-warning-over-independent-directors\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234147\" data-ts=\"1483976503\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WOOF\" target=\"_blank\">WOOF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234147-mars-vca-deal-seen-sailing-past-regulatory-review\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mars-VCA deal seen sailing past regulatory review</a></h4><ul> <li>The Mars deal to acquire VCA Antech (NASDAQ:<a href='https://seekingalpha.com/symbol/WOOF' title='VCA Antech, Inc.'>WOOF</a>) is likely to clear regulatory hurdles, says Stifel Nicolaus.</li> <li>The investment firm notes that the deal will give the combined animal services chain a market share of less than 10% in the  \"highly fragmented\" North American market.</li>  <li>Source: Bloomberg</li><li>Previously: <a href=\"https://seekingalpha.com/news/3234074-mars-acquires-vca-antech-inc\" target=\"_blank\">Mars acquires VCA Antech Inc.</a> (Jan. 9)</li><li>Shares of WOOF are <font color='green'>up 18.01%</font> to $90.58.</li></ul>   <i> </i><div class=\"tiny-share-widget\" data-id=\"3234147\" data-linked=\"Mars-VCA deal seen sailing past regulatory review\" data-tweet=\"$WOOF - Mars-VCA deal seen sailing past regulatory review https://seekingalpha.com/news/3234147-mars-vca-deal-seen-sailing-past-regulatory-review?source=tweet\" data-url=\"https://seekingalpha.com/news/3234147-mars-vca-deal-seen-sailing-past-regulatory-review\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234146\" data-ts=\"1483976249\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RDN\" target=\"_blank\">RDN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234146-private-mortgage-insurers-head-south-fha-cuts-premiums\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Private mortgage insurers head south as FHA cuts premiums</a></h4><ul><li>Radian Group (<a href='https://seekingalpha.com/symbol/RDN' title='Radian Group, Inc.'>RDN</a> <font color='red'>-3.4%</font>), MGIC Investment (<a href='https://seekingalpha.com/symbol/MTG' title='MGIC Investment Corporation'>MTG</a> <font color='red'>-2.5%</font>), Essent Group (<a href='https://seekingalpha.com/symbol/ESNT' title='Essent Group Ltd.'>ESNT</a> <font color='red'>-3.3%</font>), NMI Holdings (<a href='https://seekingalpha.com/symbol/NMIH' title='NMI Holdings, Inc.'>NMIH</a> <font color='red'>-3.6%</font>), Old Republic (<a href='https://seekingalpha.com/symbol/ORI' title='Old Republic International Corporation'>ORI</a> <font color='red'>-0.5%</font>), and Genworth (<a href='https://seekingalpha.com/symbol/GNW' title='Genworth Financial, Inc.'>GNW</a> <font color='red'>-1.3%</font>) all get a parting gift from the Obama administration <a href=\"http://www.cnbc.com/2017/01/09/federal-housing-administration-to-reduce-annual-insurance-premiums-saving-homeowners-avg-500-this-year.html\" target=\"_blank\">as the FHA cuts borrowing fees</a> by 25 basis points.</li><li>The meme for private mortgage insurers of late has been one in which they're seen as gaining market share thanks to the government's pulling back from the business of mortgage insurance. This fee reduction suggests the exact opposite.</li><li>The incoming administration, its proposed HUD Secretary Ben Carson, and the Republican congress are likely opposed to the fee reduction, but whether it actually gets reversed is a different story.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234146\" data-linked=\"Private mortgage insurers head south as FHA cuts premiums\" data-tweet=\"$RDN $RDN $MTG - Private mortgage insurers head south as FHA cuts premiums https://seekingalpha.com/news/3234146-private-mortgage-insurers-head-south-fha-cuts-premiums?source=tweet\" data-url=\"https://seekingalpha.com/news/3234146-private-mortgage-insurers-head-south-fha-cuts-premiums\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234145\" data-ts=\"1483976084\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BTU\" target=\"_blank\">BTU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234145-peabody-energy-plunges-after-update-on-reorganization-plan-support\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Peabody Energy plunges after update on reorganization plan support</a></h4><ul>     <li>Peabody Energy (BTUUQ <font color='red'>-22.6%</font>) plunges as much as 25% in early trading after providing an <a href=\"https://seekingalpha.com/pr/16707864-peabody-energy-provides-update-regarding-additional-support-plan-reorganization\" target=\"_blank\">update</a> regarding additional support for its plan of reorganization.</li>     <li>BTU says additional holders of 11.8% of the  outstanding principal amount of its senior secured second lien notes and 8% of the outstanding principal amount of its senior unsecured notes that had been granted additional time have joined the company's plan support agreement.</li>     <li>BTU says holders of 94.9% of the outstanding principal amount of senior secured second lien notes and 80.3% of the outstanding principal amount of senior unsecured notes now are parties to the PSA, backstop commitment agreement and private placement agreement.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234145\" data-linked=\"Peabody Energy plunges after update on reorganization plan support\" data-tweet=\"$BTU - Peabody Energy plunges after update on reorganization plan support https://seekingalpha.com/news/3234145-peabody-energy-plunges-after-update-on-reorganization-plan-support?source=tweet\" data-url=\"https://seekingalpha.com/news/3234145-peabody-energy-plunges-after-update-on-reorganization-plan-support\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>80&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234139\" data-ts=\"1483975079\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SSI\" target=\"_blank\">SSI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234139-stage-stores-craters-who-called\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stage Stores craters, here&#39;s who called it</a></h4><ul> <li>Stage Stores (<a href='https://seekingalpha.com/symbol/SSI' title='Stage Stores, Inc.'>SSI</a> <font color='red'>-18.8%</font>) prints an all-time low of $3.21 after <a href=\"https://seekingalpha.com/pr/16707717-stage-stores-reports-holiday-results\" target=\"_blank\">warning</a> on \"significantly\" pressured gross margins and \"weak\" traffic.</li> <li><a href=\"https://seekingalpha.com/article/4033847-stage-stores-turnaround-coming\" target=\"_blank\">SA Josh Arnold</a> advised that there was no turnaround coming for the retailer back when shares were swapping hands at around $4.40.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3234139\" data-linked=\"Stage Stores craters, here&#39;s who called it\" data-tweet=\"$SSI - Stage Stores craters, here&#39;s who called it https://seekingalpha.com/news/3234139-stage-stores-craters-who-called?source=tweet\" data-url=\"https://seekingalpha.com/news/3234139-stage-stores-craters-who-called\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234135\" data-ts=\"1483974776\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MAIN\" target=\"_blank\">MAIN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234135-baird-moves-to-sidelines-on-trio-of-hot-bdcs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Baird moves to the sidelines on trio of hot BDCs</a></h4><ul><li>Main Street Capital (<a href='https://seekingalpha.com/symbol/MAIN' title='Main Street Capital'>MAIN</a> <font color='red'>-0.7%</font>), Fidus Investment (<a href='https://seekingalpha.com/symbol/FDUS' title='Fidus Investment'>FDUS</a> <font color='red'>-4.7%</font>), and Monroe Capital (<a href='https://seekingalpha.com/symbol/MRCC' title='Monroe Capital'>MRCC</a> <font color='red'>-2.2%</font>) have all had big runs higher over the past year, but are under pressure this morning, as Baird downgrades each to Neutral from Outperform.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234135\" data-linked=\"Baird moves to the sidelines on trio of hot BDCs\" data-tweet=\"$MAIN $MAIN $FDUS - Baird moves to the sidelines on trio of hot BDCs https://seekingalpha.com/news/3234135-baird-moves-to-sidelines-on-trio-of-hot-bdcs?source=tweet\" data-url=\"https://seekingalpha.com/news/3234135-baird-moves-to-sidelines-on-trio-of-hot-bdcs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234133\" data-ts=\"1483974672\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DWDP\" target=\"_blank\">DWDP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234133-supreme-court-rejects-dow-chemical-over-1b-tax-deduction-claim\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Supreme Court rejects Dow Chemical over $1B tax deduction claim</a></h4><ul>     <li>The U.S. Supreme Court <a href=\"http://www.reuters.com/article/us-usa-court-dow-idUSKBN14T1MA\" target=\"_blank\">dismisses</a> Dow Chemical's (DOW <font color='green'>+2.1%</font>) attempt to revive its claim to $1B-plus in tax deductions based on partnerships the company formed that lower courts said were created primarily to avoid tax liability.</li>     <li>The Court left in place two rulings by the Fifth U.S. Circuit Court of Appeals in favor of the U.S. government over the two partnerships that ran during 1993-2003, agreeing with the IRS that Dow did not deserve the  tax benefits, and also imposed a 20% penalty for negligence and understatement of taxes.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3234133\" data-linked=\"Supreme Court rejects Dow Chemical over $1B tax deduction claim\" data-tweet=\"$DWDP $DD - Supreme Court rejects Dow Chemical over $1B tax deduction claim https://seekingalpha.com/news/3234133-supreme-court-rejects-dow-chemical-over-1b-tax-deduction-claim?source=tweet\" data-url=\"https://seekingalpha.com/news/3234133-supreme-court-rejects-dow-chemical-over-1b-tax-deduction-claim\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234132\" data-ts=\"1483974582\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SAM\" target=\"_blank\">SAM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234132-boston-beer-goes-flat-after-analyst-warnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Boston Beer goes flat after analyst warnings</a></h4><ul> <li>Shares of Boston Beer (<a href='https://seekingalpha.com/symbol/SAM' title='Boston Beer Co.'>SAM</a> <font color='red'>-7.6%</font>) are down sharply after William Blair <a href=\"https://www.marketbeat.com/stocks/NYSE/SAM/\" target=\"_blank\">cuts</a> the beer stock to Market Perform from Outperform.</li> <li>The investment firm warns that the depletions outlook from Boston Beer for 2016 and 2017 is at risk due.</li> <li>Susquehanna lowers it price target on SAM to $165 from $173.</li> <li>\"Despite the seemingly attractive valuation on M&amp;A and on more aggressive debt leverage, we see near term downside for SAM shares ahead of the release of 4Q16,\" warns analyst Pablo Zuanic.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3234132\" data-linked=\"Boston Beer goes flat after analyst warnings\" data-tweet=\"$SAM - Boston Beer goes flat after analyst warnings https://seekingalpha.com/news/3234132-boston-beer-goes-flat-after-analyst-warnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3234132-boston-beer-goes-flat-after-analyst-warnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234131\" data-ts=\"1483974079\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WY\" target=\"_blank\">WY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234131-weyerhaeuser-and-kite-realty-boosted-to-strong-buy-realty-income-cut-to-underperform-raymond\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weyerhaeuser and Kite Realty boosted to Strong Buy, Realty Income cut to Underperform at Raymond James</a></h4><ul><li>Weyerhaeuser (<a href='https://seekingalpha.com/symbol/WY' title='Weyerhaeuser Co.'>WY</a> <font color='green'>+0.7%</font>) is upgraded to Strong Buy with $36 price target, suggesting<font color='green'> 16% upside</font>&nbsp;from last week's close. Kite Realty Group (<a href='https://seekingalpha.com/symbol/KRG' title='Kite Realty Group Trust'>KRG</a> <font color='green'>+0.3%</font>) is also raised to Strong Buy, with $29 price target suggesting&nbsp;<font color='green'>20% upside</font>.</li><li>Lifted to Outperform are Kimco (<a href='https://seekingalpha.com/symbol/KIM' title='Kimco Realty Corporation'>KIM</a> <font color='red'>-0.3%</font>), LaSalle Hotel (<a href='https://seekingalpha.com/symbol/LHO' title='LaSalle Hotel Properties'>LHO</a> <font color='red'>-0.3%</font>), Brandywine Realty (<a href='https://seekingalpha.com/symbol/BRG' title='Bluerock Residential Growth REIT, Inc.'>BRG</a> <font color='green'>+2.2%</font>), Rayonier (<a href='https://seekingalpha.com/symbol/RYN' title='Rayonier Inc.'>RYN</a> <font color='green'>+1.1%</font>), and Washington REIT (<a href='https://seekingalpha.com/symbol/WRE' title='Washington Real Estate Investment'>WRE</a> <font color='green'>+0.5%</font>).</li><li>Downgraded to Market Perform are Cedar Realty (<a href='https://seekingalpha.com/symbol/CDR' title='Cedar Realty Trust, Inc.'>CDR</a> <font color='red'>-4.1%</font>), EastGroup (<a href='https://seekingalpha.com/symbol/EGP' title='EastGroup Properties Inc.'>EGP</a> <font color='red'>-1.1%</font>), Easterly Government Properties (<a href='https://seekingalpha.com/symbol/DEA' title='Easterly Government Properties'>DEA</a> <font color='red'>-0.7%</font>), Corporate Office Properties (<a href='https://seekingalpha.com/symbol/OFC' title='Corporate Office Properties Trust'>OFC</a> <font color='red'>-0.4%</font>), and Regency Centers (<a href='https://seekingalpha.com/symbol/REG' title='Regency Centers Corporation'>REG</a> <font color='red'>-0.7%</font>).</li><li>Cut to Underperform is Realty Income (<a href='https://seekingalpha.com/symbol/O' title='Realty Income Corporation'>O</a> <font color='red'>-0.2%</font>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3234131\" data-linked=\"Weyerhaeuser and Kite Realty boosted to Strong Buy, Realty Income cut to Underperform at Raymond James\" data-tweet=\"$WY $WY $KRG - Weyerhaeuser and Kite Realty boosted to Strong Buy, Realty Income cut to Underperform at Raymond James https://seekingalpha.com/news/3234131-weyerhaeuser-and-kite-realty-boosted-to-strong-buy-realty-income-cut-to-underperform-raymond?source=tweet\" data-url=\"https://seekingalpha.com/news/3234131-weyerhaeuser-and-kite-realty-boosted-to-strong-buy-realty-income-cut-to-underperform-raymond\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234127\" data-ts=\"1483973749\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MXL\" target=\"_blank\">MXL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234127-stifel-reissues-maxlinear-buy-increases-to-27-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stifel reissues MaxLinear at Buy, increases to $27 target</a></h4><ul><li>Citing management discussions and other recent indicators, <a href=\"http://www.streetinsider.com/Analyst+Comments/Stifel+Raises+Price+Target+on+MaxLinear+%28MXL%29+to+%2427+After+Meeting+with+Management/12406730.html\" target=\"_blank\">analyst Tore Svanberg</a>&nbsp;moves from $25 prior and&nbsp;considers MaxLinear to be moving toward Q4 2016 revenue guidance of $85M-$89M (-11.8% to -7.6% Q/Q), with gross margin expected at 63%-64% and operating expenses at $30.M (-$1M Q/Q decline). Stifel models EPS at $0.34 (<a href=\"https://finance.yahoo.com/quote/MXL/analysts?p=MXL\" target=\"_blank\">consensus $0.35</a>) for the Q4 term.</li><li>MaxLinear (NYSE:<a href='https://seekingalpha.com/symbol/MXL' title='MaxLinear, Inc.'>MXL</a>)&nbsp;<font color='green'>+2.52%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234127\" data-linked=\"Stifel reissues MaxLinear at Buy, increases to $27 target\" data-tweet=\"$MXL - Stifel reissues MaxLinear at Buy, increases to $27 target https://seekingalpha.com/news/3234127-stifel-reissues-maxlinear-buy-increases-to-27-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3234127-stifel-reissues-maxlinear-buy-increases-to-27-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234126\" data-ts=\"1483973622\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VER\" target=\"_blank\">VER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234126-jmp-reshuffles-handful-of-reit-ratings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JMP reshuffles handful of REIT ratings</a></h4><ul><li>Upgraded to Outperform are Vereit (<a href='https://seekingalpha.com/symbol/VER' title='VEREIT Inc.'>VER</a> <font color='green'>+0.2%</font>) and Wheeler Real Estate (<a href='https://seekingalpha.com/symbol/WHLR' title='Wheeler Real Estate Investment Trust'>WHLR</a> <font color='green'>+0.6%</font>).</li><li>Downgraded to Market Perform are Columbia Property Trust (<a href='https://seekingalpha.com/symbol/CXP' title='Columbia Property Trust, Inc.'>CXP</a> <font color='red'>-1.5%</font>) and Gramercy Property Trust (<a href='https://seekingalpha.com/symbol/GPT' title='Gramercy Property Trust, Inc.'>GPT</a> <font color='red'>-1.8%</font>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3234126\" data-linked=\"JMP reshuffles handful of REIT ratings\" data-tweet=\"$VER $VER $WHLR - JMP reshuffles handful of REIT ratings https://seekingalpha.com/news/3234126-jmp-reshuffles-handful-of-reit-ratings?source=tweet\" data-url=\"https://seekingalpha.com/news/3234126-jmp-reshuffles-handful-of-reit-ratings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234119\" data-ts=\"1483972636\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NMBL\" target=\"_blank\">NMBL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234119-nimble-storage-upgraded-to-overweight-pacific-crest-securities\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nimble Storage upgraded to Overweight at Pacific Crest Securities</a></h4><ul><li>From Sector Weight prior, <a href=\"http://www.streetinsider.com/Analyst+Comments/Pacific+Crest+Upgrades+Nimble+Storage+%28NMBL%29+to+Overweight/12406388.html\" target=\"_blank\">analyst Alex Kurtz</a> models Nimble Storage's contract competition at 50% from Dell EMC and considers the latter emphasizing an improved cost of sales strategy for the mid-market, suggesting decrease in direct involvement for greater-sized transactions, particularly in the $100K-$250K range. Consequently views Nimble Storage as potentially able to grow win rates among larger deals, appeal to new channel partners and escalate revenue growth near a 25% level.</li><li>Nimble Storage (NYSE:<a href='https://seekingalpha.com/symbol/NMBL' title='Nimble Storage, Inc.'>NMBL</a>)&nbsp;<font color='green'>+2.71%</font>&nbsp;early.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234119\" data-linked=\"Nimble Storage upgraded to Overweight at Pacific Crest Securities\" data-tweet=\"$NMBL - Nimble Storage upgraded to Overweight at Pacific Crest Securities https://seekingalpha.com/news/3234119-nimble-storage-upgraded-to-overweight-pacific-crest-securities?source=tweet\" data-url=\"https://seekingalpha.com/news/3234119-nimble-storage-upgraded-to-overweight-pacific-crest-securities\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234114\" data-ts=\"1483972014\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EXAS\" target=\"_blank\">EXAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234114-exact-sciences-preliminary-2016-results-beat-consensus-shares-ahead-16-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Exact Sciences&#39; preliminary 2016 results beat consensus; shares ahead 16% premarket</a></h4><ul><li>Exact Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/EXAS' title='EXACT Sciences Corporation'>EXAS</a>) is up&nbsp;<font color='green'>16%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16707907-exact-sciences-report-99-million-revenues-150-percent-growth-2016\" target=\"_blank\">announcement</a> of preliminary results for Q4 and the full year.</li><li>Q4: revenue should be $34.9M - 35.4M compared to consensus of $30.2M.</li><li>2016: revenue is expected to be $99.0M - 99.5M versus consensus of $94.2M.</li><li>244K Cologuard tests performed in 2016 (+134%).</li><li>Final results will be released next month.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234114\" data-linked=\"Exact Sciences&#39; preliminary 2016 results beat consensus; shares ahead 16% premarket\" data-tweet=\"$EXAS - Exact Sciences&#39; preliminary 2016 results beat consensus; shares ahead 16% premarket https://seekingalpha.com/news/3234114-exact-sciences-preliminary-2016-results-beat-consensus-shares-ahead-16-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3234114-exact-sciences-preliminary-2016-results-beat-consensus-shares-ahead-16-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234110\" data-ts=\"1483971742\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AYI\" target=\"_blank\">AYI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234110-acquity-brands-lower-on-earnings-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Acquity Brands lower on earnings miss</a></h4><ul>     <li>Acuity Brands (NYSE:<a href='https://seekingalpha.com/symbol/AYI' title='Acuity Brands, Inc. &#40;Holding Company&#41;'>AYI</a>) reports revenue rose 16% due to 10% increase in volume and approx. 9% contribution from acquired revenues from acquisitions in <a href=\"https://seekingalpha.com/pr/16708424-acuity-brands-reports-record-first-quarter-results\" target=\"_blank\">FQ1</a>.</li>     <li>Sales of LED-based products represented two-third of total net sales.</li>     <li>Gross margin rate slipped 100 bps to 42.4%.</li>     <li>Adjusted SD&amp;A expense rate improved 80 bps to 25.6%.</li>     <li>Adjusted operating margin rate declined 30 bps 16.8%.</li>     <li>AYI&nbsp;<font color='red'>-10.68%</font>&nbsp;premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3234110\" data-linked=\"Acquity Brands lower on earnings miss\" data-tweet=\"$AYI - Acquity Brands lower on earnings miss https://seekingalpha.com/news/3234110-acquity-brands-lower-on-earnings-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3234110-acquity-brands-lower-on-earnings-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234103\" data-ts=\"1483971533\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMAG\" target=\"_blank\">AMAG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234103-amag-2016-top-line-may-be-bit-light-versus-consensus-shares-ease-11-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AMAG 2016 top line may be a bit light versus consensus; shares ease 11% premarket</a></h4><ul><li>AMAG Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/AMAG' title='AMAG Pharmaceuticals, Inc.'>AMAG</a>) slumps&nbsp;<font color='red'>11%</font>&nbsp;premarket on average volume in response to its <a href=\"https://seekingalpha.com/pr/16708341-amag-pharmaceuticals-provides-financial-business-update\" target=\"_blank\">announcement </a>of preliminary Q4 and full-year results and guidance for 2017.</li><li>Q4: revenues: $149M - 154M versus consensus of $154.9M. Makena sales: $96M - 99M.</li><li>2016 revenues: $529M - 551M versus consensus of $551.3M.</li><li>2017 guidance: revenues: $620M - 670M; operating income: $103M - 173M; net income: $19M - 60M.</li><li>#JPM17</li></ul><div class=\"tiny-share-widget\" data-id=\"3234103\" data-linked=\"AMAG 2016 top line may be a bit light versus consensus; shares ease 11% premarket\" data-tweet=\"$AMAG - AMAG 2016 top line may be a bit light versus consensus; shares ease 11% premarket https://seekingalpha.com/news/3234103-amag-2016-top-line-may-be-bit-light-versus-consensus-shares-ease-11-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3234103-amag-2016-top-line-may-be-bit-light-versus-consensus-shares-ease-11-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234107\" data-ts=\"1483971524\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HIMX\" target=\"_blank\">HIMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234107-himax-technologies-downgraded-northland-capital-markets\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Himax Technologies downgraded at Northland Capital Markets</a></h4><ul><li><a href=\"http://www.streetinsider.com/Downgrades/Northland+Capital+Markets+Downgrades+Himax+Technologies+%28HIMX%29+to+Market+Perform/12406436.html\" target=\"_blank\">From Outperform</a> to Market Perform.</li><li>Himax Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/HIMX' title='Himax Technologies, Inc.'>HIMX</a>)&nbsp;<font color='red'>-1.82%</font>&nbsp;pre-market.</li><li>Prior Northland Capital Markets commentary (October 11, 2016) &ndash; <a href=\"https://seekingalpha.com/news/3213381-himax-technologies-minus-4-percent-northland-capital-markets-lowers-2016-2017-estimates\" target=\"_blank\">Himax Technologies -4%; Northland Capital Markets lowers 2016, 2017 estimates</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3234107\" data-linked=\"Himax Technologies downgraded at Northland Capital Markets\" data-tweet=\"$HIMX - Himax Technologies downgraded at Northland Capital Markets https://seekingalpha.com/news/3234107-himax-technologies-downgraded-northland-capital-markets?source=tweet\" data-url=\"https://seekingalpha.com/news/3234107-himax-technologies-downgraded-northland-capital-markets\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234104\" data-ts=\"1483971304\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234104-premarket-gainers-losers-of-9-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers / Losers as of 9:10 am</a></h4><ul> <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ARIA' title='ARIAD Pharmaceuticals, Inc.'>ARIA</a> <font color='green'>+74%</font>. <a href='https://seekingalpha.com/symbol/MACK' title='Merrimack Pharmaceuticals'>MACK</a> <font color='green'>+34%</font>. <a href='https://seekingalpha.com/symbol/WOOF' title='VCA Antech, Inc.'>WOOF</a> <font color='green'>+29%</font>. <a href='https://seekingalpha.com/symbol/PRPH' title='ProPhase Labs, Inc.'>PRPH</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/XGTI' title='xG Technology, Inc.'>XGTI</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/EXAS' title='EXACT Sciences Corporation'>EXAS</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/PTX' title='Pernix Therapeutics Holdings, Inc.'>PTX</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/KERX' title='Keryx Biopharmaceuticals, Inc.'>KERX</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/SINO' title='Sino-Global Shipping America, Ltd.'>SINO</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/INCY' title='Incyte Corporation'>INCY</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/NAK' title='Northern Dynasty Minerals Ltd'>NAK</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/GEVO' title='Gevo, Inc.'>GEVO</a> <font color='green'>+6%</font>. ETRM <font color='green'>+4%</font>. <a href='https://seekingalpha.com/symbol/EXEL' title='Exelixis, Inc.'>EXEL</a> <font color='green'>+5%</font>.</li> <li><b>Losers:</b> ADHD <font color='red'>-21%</font>. GALE <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/AMAG' title='AMAG Pharmaceuticals, Inc.'>AMAG</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/RWLK' title='ReWalk Robotics'>RWLK</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/FIVE' title='Five Below'>FIVE</a> <font color='red'>-6%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3234104\" data-linked=\"Premarket Gainers / Losers as of 9:10 am\" data-tweet=\"$ARIA $MACK $WOOF - Premarket Gainers / Losers as of 9:10 am https://seekingalpha.com/news/3234104-premarket-gainers-losers-of-9-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3234104-premarket-gainers-losers-of-9-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234101\" data-ts=\"1483970703\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234101-feds-rosengren-calls-for-faster-pace-of-rate-hikes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fed&#39;s Rosengren calls for faster pace of rate hikes</a></h4><ul><li>The data are likely to warrant \"somewhat more regular\" interest rate increases, <a href=\"https://www.bostonfed.org/news-and-events/speeches/2017/current-economic-conditions-and-the-implications-for-monetary-policy.aspx\" target=\"_blank\">says Boston Fed President Eric Rosengren</a>.</li><li>He expects the central bank to hit both its employment and inflation targets by the end of this year.</li><li>Yields, meanwhile, are slipping this morning, with the 10-year Treasury down five basis points to 2.37%. Fed Funds futures <a href=\"http://www.cmegroup.com/trading/interest-rates/stir/30-day-federal-fund.html\" target=\"_blank\">continue to price in </a>just two rates hikes in 2017.</li><li><a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a>&nbsp;<font color='green'>+0.8%</font>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a>&nbsp;<font color='red'>-1.6%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3234101\" data-linked=\"Fed&#39;s Rosengren calls for faster pace of rate hikes\" data-tweet=\"$TLT $TBT - Fed&#39;s Rosengren calls for faster pace of rate hikes https://seekingalpha.com/news/3234101-feds-rosengren-calls-for-faster-pace-of-rate-hikes?source=tweet\" data-url=\"https://seekingalpha.com/news/3234101-feds-rosengren-calls-for-faster-pace-of-rate-hikes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234090\" data-ts=\"1483970565\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VNDA\" target=\"_blank\">VNDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234090-vanda-pharmaceuticals-reports-preliminary-q4-and-fy2016-results-and-2017-guidance-shares-up-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vanda Pharmaceuticals reports preliminary Q4 and FY2016 results and 2017 guidance; shares up 4% premarket</a></h4><ul><li>Vanda Pharmaceuticals&nbsp;(NASDAQ:<a href='https://seekingalpha.com/symbol/VNDA' title='Vanda Pharmaceuticals Inc.'>VNDA</a>) <a href=\"https://seekingalpha.com/pr/16708113-vanda-pharmaceuticals-reports-preliminary-fourth-quarter-full-year-2016-revenue-results-2017\" target=\"_blank\">announces</a> preliminary unaudited financial results for Q4 and FY2016 and its financial guidance for 2017 as follows:</li><li>Vanda expects to report Q4 and FY2016 total net product sales&nbsp;of ~$38M and ~$146M respectively, consistent with Vanda's prior FY2016 guidance of $143M - $153M.</li><li>Q4 and FY2016 HETLIOZ&nbsp;net product sales of ~$19M and ~$72M respectively, as compared to prior FY2016 guidance of $73M - $78M.</li><li>Q4 and FY2016 Fanapt&nbsp;net product sales of ~$19M and ~$74M respectively, as compared to prior FY2016 guidance of $70M - $75M.</li><li>Cash, cash equivalents and marketable securities of ~$141M, a decrease of ~$2M.</li><li>The company also expects following 2017 financial guidance: Net product sales&nbsp;of $165M - $175M, HETLIOZ&nbsp;net product sales of $88M - $93M,&nbsp;Fanapt&nbsp;net product sales of $77M - $82M. Non-GAAP Operating expenses of $162M - $172M.</li><li>Shares are up&nbsp;<font color='green'>4%</font>&nbsp;premarket.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3234090\" data-linked=\"Vanda Pharmaceuticals reports preliminary Q4 and FY2016 results and 2017 guidance; shares up 4% premarket\" data-tweet=\"$VNDA - Vanda Pharmaceuticals reports preliminary Q4 and FY2016 results and 2017 guidance; shares up 4% premarket https://seekingalpha.com/news/3234090-vanda-pharmaceuticals-reports-preliminary-q4-and-fy2016-results-and-2017-guidance-shares-up-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3234090-vanda-pharmaceuticals-reports-preliminary-q4-and-fy2016-results-and-2017-guidance-shares-up-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234094\" data-ts=\"1483970044\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIVE\" target=\"_blank\">FIVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234094-five-below-updates-guidance-ahead-of-icr\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Five Below updates guidance ahead of ICR</a></h4><ul> <li>Five Below (NASDAQ:<a href='https://seekingalpha.com/symbol/FIVE' title='Five Below'>FIVE</a>) announces that holiday period sales increased 18.0% to $349.3M.</li><li>Comparable sales for the period rose 0.5%.</li>  <li>\"After a solid start to the holiday season, we experienced softness in mid-December, including Super Saturday, with sales accelerating later in the holiday season, ' says CEO Joel Anderson.</li><li>The company now sees Q4 EPS of $0.88 to $0.89 vs. $0.91 consensus.</li>    <li>For FY16, sales are now expected to fall in a range of $998M-$1.00B. EPS of $1.28 to $1.29 is forecast vs. $1.29-$1.32 prior and $1.31 consensus.</li><li>FIVE  <font color='red'>-1.54%</font> premarket to  $39.11.</li><li><a href=\"https://seekingalpha.com/news/search?query=ICR17\" target=\"_blank\">#ICR17</a></li><li>Source: <a href=\"https://seekingalpha.com/pr/16708380-five-inc-announces-holiday-sales-results-quarter-date-january-7-2017-updates-fourth-quarter\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3234094\" data-linked=\"Five Below updates guidance ahead of ICR\" data-tweet=\"$FIVE - Five Below updates guidance ahead of ICR https://seekingalpha.com/news/3234094-five-below-updates-guidance-ahead-of-icr?source=tweet\" data-url=\"https://seekingalpha.com/news/3234094-five-below-updates-guidance-ahead-of-icr\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:54 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234091\" data-ts=\"1483969301\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARWR\" target=\"_blank\">ARWR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234091-arrowhead-up-8-premarket-on-news-of-silence-therapeutics-investment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arrowhead up 8% premarket on news of Silence Therapeutics investment</a></h4><ul><li>Arrowhead Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ARWR' title='Arrowhead Pharmaceuticals'>ARWR</a>) perks up&nbsp;<font color='green'>8%</font>&nbsp;premarket on increased volume in response to the <a href=\"https://seekingalpha.com/pr/16707981-arrowhead-provides-response-new-minority-shareholder-announcement\" target=\"_blank\">news </a>that London-based&nbsp;<a href=\"http://www.silence-therapeutics.com/\" target=\"_blank\">Silence Therapeutics</a> has acquired ~6M ARWR common shares representing an 8.4% stake. Arrowhead was advised of the development just prior to an announcement by Silence.</li><li>Arrowhead says there have been no discussions about a potential transaction. President &amp; CEO Chris Anzalone says, \"We remain focused on advancing our programs in a way that maximizes stockholder value. While we welcome Silence as a stockholder, its recently announced stake in Arrowhead does not change our focus or strategic plans in any way.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3234091\" data-linked=\"Arrowhead up 8% premarket on news of Silence Therapeutics investment\" data-tweet=\"$ARWR - Arrowhead up 8% premarket on news of Silence Therapeutics investment https://seekingalpha.com/news/3234091-arrowhead-up-8-premarket-on-news-of-silence-therapeutics-investment?source=tweet\" data-url=\"https://seekingalpha.com/news/3234091-arrowhead-up-8-premarket-on-news-of-silence-therapeutics-investment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234088\" data-ts=\"1483968835\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JD\" target=\"_blank\">JD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234088-j-p-morgan-upgrades-jd-com-to-overweight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">J.P. Morgan upgrades JD.com to Overweight</a></h4><ul><li>From Neutral, <a href=\"http://www.streetinsider.com/Analyst+Comments/UPDATE%3A+JPMorgan+Upgrades+JD.com%2C+Inc+%28JD%29+to+Overweight%2C+Expects+RMB700m+Cost+Saving+From+JD+Finance+Spin-Off/12405613.html\" target=\"_blank\">analyst Alex Yao</a> highlights 1P momentum in 2017 (specifically FMCG and home appliance segments), growing scale lending to greater purchase power and 1P gross margin he projects to rise by 70 bps and 40 bps in 2017 and 2018, respectively.</li><li>Considers competition with Alibaba to remain a risk, though one that is unlikely to rise in the current year due to 1P exposure restricted to FMCG and impact on 3P that had maximized in 2016. Models competition impact at 48%&nbsp;of 2017 net profit.</li><li>Raises target to $39 from $32.</li><li>JD.com (NASDAQ:<a href='https://seekingalpha.com/symbol/JD' title='JD.com'>JD</a>) pre-market&nbsp;<font color='green'>+2.51%</font>&nbsp;to $26.93.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234088\" data-linked=\"J.P. Morgan upgrades JD.com to Overweight\" data-tweet=\"$JD - J.P. Morgan upgrades JD.com to Overweight https://seekingalpha.com/news/3234088-j-p-morgan-upgrades-jd-com-to-overweight?source=tweet\" data-url=\"https://seekingalpha.com/news/3234088-j-p-morgan-upgrades-jd-com-to-overweight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:33 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234086\" data-ts=\"1483968671\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ET\" target=\"_blank\">ET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234086-energy-transfer-equity-buys-568m-in-mlp-units-via-private-placement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy Transfer Equity buys $568M in MLP units via private placement</a></h4><ul>     <li>Energy Transfer Partners (ETP) announces a <a href=\"https://seekingalpha.com/pr/16708354-energy-transfer-partners-l-p-announces-private-placement-568-million-common-units-energy\" target=\"_blank\">private placement of $568M of common units</a> with Energy Transfer Equity (ETE), in which ETP will receive $568M in gross proceeds in exchange for the issuance to ETE of ~15.8M ETP common  units.</li>          <li>The purchase price per unit is equal to the volume weighted average trading price of ETP&rsquo;s common units for the 10 trading day period ending Jan. 5.</li>     <li>ETE <font color='red'>-1.8%</font>, ETP <font color='red'>-0.3%</font> premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3234086\" data-linked=\"Energy Transfer Equity buys $568M in MLP units via private placement\" data-tweet=\"$ET - Energy Transfer Equity buys $568M in MLP units via private placement https://seekingalpha.com/news/3234086-energy-transfer-equity-buys-568m-in-mlp-units-via-private-placement?source=tweet\" data-url=\"https://seekingalpha.com/news/3234086-energy-transfer-equity-buys-568m-in-mlp-units-via-private-placement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>64&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234084\" data-ts=\"1483968539\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234084-rough-session-for-pound-after-mays-weekend-comments\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rough session for pound after May&#39;s weekend comments</a></h4><ul><li>Exiting the EU will be \"getting the right relationship, not about keeping bits of membership,\" U.K. Prime Minister Theresa May <a href=\"https://www.bloomberg.com/news/articles/2017-01-09/pound-falls-to-10-week-low-as-may-hints-at-single-market-exit\" target=\"_blank\">told Sky News over</a> the weekend.</li><li>\"The aim of controlling immigration was a red line she would not be willing to cross,&rdquo; says a currency strategist, meaning the U.K. is likely to lose access to the single market once Brexit occurs.<br>&ldquo;A hard Brexit looks almost certain,&rdquo; says UniCredit. &ldquo;The only real question that remains is whether the transition will be gradual (and, hence, orderly) or abrupt.\"</li><li>The pound is&nbsp;<font color='red'>lower by 1.2%</font>&nbsp;to $1.2139. The FTSE 100 is&nbsp;<font color='green'>ahead 0.3%</font>.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/FXB' title='CurrencyShares British Pound Sterling Trust ETF'>FXB</a>, <a href='https://seekingalpha.com/symbol/EWU' title='iShares MSCI United Kingdom ETF'>EWU</a>, <a href='https://seekingalpha.com/symbol/GBB' title='iPath GBP/USD Exchange Rate ETN'>GBB</a>, <a href='https://seekingalpha.com/symbol/EWUS' title='iShares MSCI United Kingdom Small Cap Index ETF'>EWUS</a>, <a href='https://seekingalpha.com/symbol/FKU' title='First Trust United Kingdom AlphaDex ETF'>FKU</a>, <a href='https://seekingalpha.com/symbol/DXPS' title='WisdomTree United Kingdom Hedged Equity ETF'>DXPS</a>, <a href='https://seekingalpha.com/symbol/DBUK' title='Deutsche X-trackers MSCI United Kingdom Hedged Equity ETF'>DBUK</a>, <a href='https://seekingalpha.com/symbol/QGBR' title='SPDR MSCI United Kingdom Quality Mix ETF'>QGBR</a>, <a href='https://seekingalpha.com/symbol/HEWU' title='iShares Currency Hedged MSCI United Kingdom ETF'>HEWU</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3234084\" data-linked=\"Rough session for pound after May&#39;s weekend comments\" data-tweet=\"$FXB $EWU $GBB - Rough session for pound after May&#39;s weekend comments https://seekingalpha.com/news/3234084-rough-session-for-pound-after-mays-weekend-comments?source=tweet\" data-url=\"https://seekingalpha.com/news/3234084-rough-session-for-pound-after-mays-weekend-comments\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234083\" data-ts=\"1483968468\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SLS\" target=\"_blank\">SLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234083-galena-subject-in-criminal-investigation-abstral-promotional-practices-shares-off-18\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Galena subject in criminal investigation into Abstral promotional practices; shares off 18% premarket</a></h4><ul><li>Galena Biopharma (GALE) slumps&nbsp;<font color='red'>18%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://www.sec.gov/Archives/edgar/data/1390478/000139047817000002/gale-201701068xk.htm\" target=\"_blank\">disclosure</a> that the U.S. Attorney's Office for the District of New Jersey and the U.S. Department of Justice have launched a criminal investigation, in additional to a civil investigation, into the marketing and promotional practices related to opioid <a href=\"http://www.sentynl.com/abstral/\" target=\"_blank\">Abstral </a>(fentanyl) sublingual tablets.</li><li>The investigation is assessing possible violations of the federal False Claims Act, the federal Anti-Kickback Statute and the federal Sunshine Act.</li><li>The company has received a subpoena for documents related to the criminal prosecution of two high-prescribing physicians that commenced on January 4. It says that it intends to cooperate fully with the inquiry.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234083\" data-linked=\"Galena subject in criminal investigation into Abstral promotional practices; shares off 18% premarket\" data-tweet=\"$SLS - Galena subject in criminal investigation into Abstral promotional practices; shares off 18% premarket https://seekingalpha.com/news/3234083-galena-subject-in-criminal-investigation-abstral-promotional-practices-shares-off-18?source=tweet\" data-url=\"https://seekingalpha.com/news/3234083-galena-subject-in-criminal-investigation-abstral-promotional-practices-shares-off-18\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1576990800,"end":1577077199,"str":"Sunday, December 22, 2019"},"yesterday":{"start":1576904400,"end":1576990799}}